prednisone has been researched along with Glomerulonephritis, Lupus in 212 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)." | 9.51 | Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022) |
| "A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 9.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
| "Intravenous cyclophosphamide with prednisone is an effective treatment for lupus nephritis, but with significant toxicities." | 9.15 | Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. ( Chen, J; Chen, W; Fan, A; Fu, J; Fu, P; Kong, Y; Li, Z; Liao, Y; Liu, F; Liu, Q; Liu, Z; Lou, T; Rao, S; Tang, X; Yang, Z; Yu, X; Zhang, J, 2011) |
| "With extended follow-up, pulse cyclophosphamide continued to show superior efficacy over pulse methylprednisolone alone for treatment of lupus nephritis." | 9.09 | Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. ( Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001) |
| "To describe the clinical course of severe lupus nephritis and to identify the risk factors for progression to renal failure among patients treated with prednisone and short-term courses of low-dose oral cyclophosphamide." | 9.07 | Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. ( Corwin, HL; Hunsicker, LG; Kasinath, BS; Lachin, J; Lan, SP; Levey, AS; Lewis, EJ; Neilson, EG, 1992) |
| "The existing guidelines for lupus nephritis (LN) recommend initial prednisone doses of 0." | 8.12 | Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis. ( Al-Sheikh, H; Gladman, DD; Su, J; Tselios, K; Urowitz, MB, 2022) |
| "Mycophenolic acid (MPA) is an effective oral immunosuppressive drug used to treat lupus nephritis (LN), which exhibits large pharmacokinetic variability." | 7.96 | Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ( Abud-Mendoza, C; Martínez-Martínez, MU; Medellín-Garibay, SE; Milán-Segovia, RDC; Reséndiz-Galván, JE; Romano-Aguilar, M; Romano-Moreno, S, 2020) |
| "A combination of medium-dose prednisone, methylprednisolone pulses, cyclophosphamide and hydroxychloroquine is at least as effective in achieving remission of lupus nephritis as regimes containing high-dose prednisone and causes less toxicity." | 7.80 | Prednisone in lupus nephritis: how much is enough? ( Danza, A; Delgado, S; Garcia, M; Khamashta, M; Perales, I; Ruiz-Irastorza, G; Villar, I, 2014) |
| "To investigate the effects of Artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice." | 7.78 | [Effect of artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice]. ( An, P; Qiao, CL; Shi, XM; Sun, WS; Wang, Z; Wu, XL, 2012) |
| "To investigate the therapeutic effects and mechanisms of using artemisinin (Art) combined with glucocorticoid (GC) to treat lupus nephritis (LN) mice." | 7.77 | Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice. ( An, P; Qiao, CL; Shi, XM; Sun, WS; Wang, Z; Wu, XL; Zhang, WG, 2011) |
| "To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis." | 7.72 | Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003) |
| "It has been reported that outcomes are improved in patients with severe lupus nephritis treated with combined prednisone and intravenous cyclophosphamide, compared with those treated with prednisone alone." | 7.69 | The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. ( Klippel, JH; McInnes, PM; Sanslone, WR; Schuttinga, J; Stark, SP, 1994) |
| ") methylprednisolone (MP) pulses followed by low dose oral prednisone (PRED) was assessed in a group of patients with active lupus nephritis (LN)." | 7.69 | Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study. ( Bertoni, E; Bertoni, M; Brugnolo, F; Emmi, L; Romagnani, S; Salvadori, M, 1994) |
| "For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares." | 6.72 | A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006) |
| "For the treatment of proliferative lupus nephritis, long-term cyclophosphamide (CY) regimens are efficacious, however, at the expense of substantial toxicity." | 6.71 | Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. ( Contreras, G; Metz, D; Nahar, N; Tozman, E, 2005) |
| "Previous studies have compared mycophenolate mofetil and azathioprine as maintenance therapy for lupus nephritis (LN)." | 5.51 | Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up. ( Bao, C; Dai, L; Dai, M; Fu, Q; He, L; Li, Z; Lu, L; Sun, L; Wang, S; Wu, C; Xu, J; Zhu, X, 2022) |
| "The BC followed international lupus nephritis guidelines, combining high-dose prednisone and either mycophenolate mofetil or cyclophosphamide, followed by maintenance therapy with low dose prednisone and immunosuppressive drugs." | 5.46 | Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. ( Blanco, P; Couzi, L; Iza, A; Lazaro, E; Porta, S; Richez, C; Ruiz-Irastorza, G; Saenz, R; Saint-Pastou Terrier, C; Ugarte, A, 2017) |
| " The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients." | 5.46 | The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. ( Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017) |
| "Proteinuria was 2." | 5.38 | The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. ( Bob, F; Bozdog, G; Cioca, D; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Marian, R; Petrica, L; Velciov, S; Vernic, C, 2012) |
| "The treatment of membranous lupus nephritis (MLN) is still controversial in the literature." | 5.37 | Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011) |
| "Nine patients with diffuse proliferative lupus nephritis confirmed by renal biopsy received MMF/prednisone for six months when repeat biopsies were performed." | 5.32 | Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. ( Ding, L; Liu, Y; Wang, H; Zhao, M; Zou, W, 2004) |
| "A prospective, multi-center, randomized controlled study was conducted to evaluate the efficacy and safety of a 24-week course low-dose leflunomide combined with prednisone in the induction treatment of proliferative lupus nephritis in Chinese patients." | 5.30 | Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial. ( Chen, J; Chen, Q; Guan, T; Jiang, G; Li, D; Luo, P; Ni, Z; Qi, C; Sun, M; Sun, Z; Wan, J; Wang, L; Wang, S; Xing, C; Zha, Y; Zhang, M, 2019) |
| "Intravenous cyclophosphamide with prednisone is an effective treatment for lupus nephritis, but with significant toxicities." | 5.15 | Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. ( Chen, J; Chen, W; Fan, A; Fu, J; Fu, P; Kong, Y; Li, Z; Liao, Y; Liu, F; Liu, Q; Liu, Z; Lou, T; Rao, S; Tang, X; Yang, Z; Yu, X; Zhang, J, 2011) |
| "A combination of prednisone and AZA is reasonably effective for the initial treatment of pure membranous lupus nephritis." | 5.11 | Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. ( Au, TC; Lau, CS; Mok, CC; Ng, WL; Wong, WS; Yim, CW; Ying, KY, 2004) |
| "For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide." | 5.11 | Sequential therapies for proliferative lupus nephritis. ( Contreras, G; Leclercq, B; Lenz, O; O'Nan, P; Pardo, V; Roth, D; Tozman, E, 2004) |
| "With extended follow-up, pulse cyclophosphamide continued to show superior efficacy over pulse methylprednisolone alone for treatment of lupus nephritis." | 5.09 | Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. ( Austin, HA; Balow, JE; Boumpas, DT; Collins, L; Crane, M; Danning, CL; Gourley, MF; Illei, GG; Klippel, JH; Kuroiwa, T; Steinberg, AD; Vaughan, EM; Yarboro, CH, 2001) |
| "We carried out a randomized, controlled trial comparing a standard-therapy regimen of prednisone and cyclophosphamide (standard therapy) with a regimen of standard therapy plus plasmapheresis in 86 patients with severe lupus nephritis in 14 medical centers." | 5.07 | A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. ( Hunsicker, LG; Lachin, JM; Lan, SP; Lewis, EJ; Rohde, RD, 1992) |
| "To describe the clinical course of severe lupus nephritis and to identify the risk factors for progression to renal failure among patients treated with prednisone and short-term courses of low-dose oral cyclophosphamide." | 5.07 | Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. ( Corwin, HL; Hunsicker, LG; Kasinath, BS; Lachin, J; Lan, SP; Levey, AS; Lewis, EJ; Neilson, EG, 1992) |
| " The last drug was substituted with azathioprine in prevision of pregnancy." | 4.91 | Pregnancies in women receiving renal transplant for lupus nephritis: description of nine pregnancies and review of the literature. ( Campise, M; Giglio, E; Messa, P; Moroni, G; Trespidi, L, 2015) |
| "The Jieduquyuziyin prescription (JP), a traditional Chinese medicine (TCM) formula, has been used as an approved hospital prescription to improve the efficacy of prednisone (Pred) in systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment." | 4.12 | Jieduquyuziyin prescription promotes the efficacy of prednisone via upregulating Nrf2 in MRL/lpr kidneys. ( Du, L; Feng, Y; He, Z; Shi, X; Wang, C; Wen, C; Zhang, Y, 2022) |
| "The existing guidelines for lupus nephritis (LN) recommend initial prednisone doses of 0." | 4.12 | Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis. ( Al-Sheikh, H; Gladman, DD; Su, J; Tselios, K; Urowitz, MB, 2022) |
| "Combination therapy with mycophenolate mofetil, tacrolimus and steroids are effective in achieving complete remission in lupus nephritis (LN)." | 4.02 | Novel Effects of Combination Therapy Through Inhibition of Caspase-1/Gasdermin D Induced-Pyroptosis in Lupus Nephritis. ( Cao, H; He, Y; Jiang, S; Ke, Y; Liang, J; Lin, J; Liu, J; Sun, Y, 2021) |
| "Serious renal pathological changes, mass proteinuria, higher SLEDAI, higher prednisone dose, and a decline in CD4+ T cells could be risk factors for CM in patients with LN." | 3.96 | Cryptococcal meningitis in patients with lupus nephritis. ( Chen, J; Chen, P, 2020) |
| "Mycophenolic acid (MPA) is an effective oral immunosuppressive drug used to treat lupus nephritis (LN), which exhibits large pharmacokinetic variability." | 3.96 | Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ( Abud-Mendoza, C; Martínez-Martínez, MU; Medellín-Garibay, SE; Milán-Segovia, RDC; Reséndiz-Galván, JE; Romano-Aguilar, M; Romano-Moreno, S, 2020) |
| "A recent clinical study showed that combination therapy consisting of mycophenolate mofetil, tacrolimus and steroids was shown to be more effective in achieving complete remission in patients with severe forms of lupus nephritis than conventional therapy consisting of intravenous cyclophosphamide and steroids." | 3.88 | Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. ( Cai, M; Chuang, PY; Fu, J; He, JC; Lee, K; Liu, Z; Ma'ayan, A; Wang, Z; Wei, C; Zhang, M; Zhang, W; Zhou, M, 2018) |
| "A combination of medium-dose prednisone, methylprednisolone pulses, cyclophosphamide and hydroxychloroquine is at least as effective in achieving remission of lupus nephritis as regimes containing high-dose prednisone and causes less toxicity." | 3.80 | Prednisone in lupus nephritis: how much is enough? ( Danza, A; Delgado, S; Garcia, M; Khamashta, M; Perales, I; Ruiz-Irastorza, G; Villar, I, 2014) |
| "9 g 24-h proteinuria while still in remission of the protein-losing enteropathy, receiving 5 mg prednisone and 100 mg azathioprine daily." | 3.78 | Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus. ( Braga, LL; Brandão, LA; Carneiro, FO; Rocha, FA; Sampaio, LR, 2012) |
| "To investigate the effects of Artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice." | 3.78 | [Effect of artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice]. ( An, P; Qiao, CL; Shi, XM; Sun, WS; Wang, Z; Wu, XL, 2012) |
| "To investigate the therapeutic effects and mechanisms of using artemisinin (Art) combined with glucocorticoid (GC) to treat lupus nephritis (LN) mice." | 3.77 | Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice. ( An, P; Qiao, CL; Shi, XM; Sun, WS; Wang, Z; Wu, XL; Zhang, WG, 2011) |
| "(1) Those patients with unstable status progestation, patients being newly diagnosed with SLE during pregnancy or patients irregularly using prednisone became active during pregnancy." | 3.73 | [Influential factors of systemic lupus erythematosus activity during pregnancy and its relationship with pregnancy outcome]. ( Tan, JP; Wang, YH; Wu, XX; Zhang, JP, 2006) |
| "To evaluate the efficacy of pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis." | 3.72 | Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. ( Aviña-Zubieta, JA; Bustamante, R; Esquivel-Nava, G; Galindo-Rodríguez, G; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J, 2003) |
| "Seven lupus nephritis patients who failed to respond to at least prednisone and cyclophosphamide were studied." | 3.70 | Intravenous immunoglobulin treatment of lupus nephritis. ( Fabbrizzi, F; George, J; Langevitz, P; Levy, Y; Lukac, J; Poprac, P; Rauova, L; Rovensky, J; Sherer, Y; Shoenfeld, Y, 2000) |
| "It has been reported that outcomes are improved in patients with severe lupus nephritis treated with combined prednisone and intravenous cyclophosphamide, compared with those treated with prednisone alone." | 3.69 | The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide. ( Klippel, JH; McInnes, PM; Sanslone, WR; Schuttinga, J; Stark, SP, 1994) |
| ") methylprednisolone (MP) pulses followed by low dose oral prednisone (PRED) was assessed in a group of patients with active lupus nephritis (LN)." | 3.69 | Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study. ( Bertoni, E; Bertoni, M; Brugnolo, F; Emmi, L; Romagnani, S; Salvadori, M, 1994) |
| "Twenty-two patients with histologically demonstrated diffuse proliferative lupus nephritis (DPLN) and glomerular thrombosis received a 14-day course of ancrod, followed in most by nitrogen mustard (mechlorethamine hydrochloride) 0." | 3.68 | Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod. ( Hariharan, S; Kant, KS; Pollak, VE; Wadhwa, NK; Weiss, MA, 1990) |
| "Optimal treatment for pure membranous lupus nephritis (MLN) remains unknown." | 2.82 | Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. ( Córdova-Sánchez, BM; Correa-Rotter, R; Mejía-Vilet, JM; Uribe-Uribe, NO, 2016) |
| "Treatment of lupus nephritis (LN) remains challenging." | 2.80 | Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. ( Bao, H; Chen, J; Chen, N; Fu, P; Gu, Y; He, Y; Hu, W; Li, Y; Lin, H; Liu, F; Liu, Z; Miao, L; Ni, Z; Shi, W; Xing, C; Zeng, C; Zhang, H; Zhou, M, 2015) |
| "Prednisone alone was administered and dose-adjusted to control extrarenal manifestations." | 2.77 | Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. ( Brinks, R; Chehab, G; Fischer-Betz, R; Sander, O; Schneider, M; Voiculescu, A; Vordenbäumen, S, 2012) |
| "Class V lupus nephritis (LN) occurs in one-fifth of biopsy-proven cases of systemic lupus erythematosus." | 2.75 | Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. ( Appel, GB; Ginzler, EM; Moutzouris, DA; Radhakrishnan, J; Siempos, II; Solomons, N, 2010) |
| "Patients with active lupus nephritis (renal biopsy class III, IV, or V) were recruited for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclophosphamide (0." | 2.75 | Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. ( Dooley, MA; Ginzler, EM; Gordon, C; Isenberg, D; Lisk, L; Wofsy, D, 2010) |
| "Median proteinuria was 5." | 2.74 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. ( Austin, HA; Balow, JE; Braun, MJ; Illei, GG, 2009) |
| "Treatment of class V+IV lupus nephritis remains unsatisfactory despite the progress made in the treatment of diffuse proliferative lupus nephritis." | 2.73 | Successful treatment of class V+IV lupus nephritis with multitarget therapy. ( Bao, H; Hu, WX; Li, LS; Liu, ZH; Xie, HL; Zhang, HT, 2008) |
| "For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares." | 2.72 | A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. ( Alberighi, OD; Altieri, P; Doria, A; Ferraccioli, G; Ferrara, R; Greco, S; Manno, C; Moroni, G; Mosca, M; Ponticelli, C; Todesco, S, 2006) |
| "For the treatment of proliferative lupus nephritis, long-term cyclophosphamide (CY) regimens are efficacious, however, at the expense of substantial toxicity." | 2.71 | Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. ( Contreras, G; Metz, D; Nahar, N; Tozman, E, 2005) |
| "Eleven children with various forms of lupus nephritis were treated with oral MMF at a mean dose of 22 mg/kg/day (range 17-42) for a mean of 9." | 2.70 | Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. ( Bartosh, S; Buratti, S; Reiff, A; Spencer, CH; Szer, IS, 2001) |
| "Forty-seven patients with lupus nephritis and abnormal serum creatinine or elevated 24-hr urine protein were enrolled." | 2.69 | Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis. ( Lan, JL; Lin, WY; Wang, SJ, 1998) |
| " Prednisolone dosage was gradually tapered to 10 mg/d at 6 months, when cyclophosphamide was replaced by azathioprine (2 mg/kg/d p." | 2.69 | Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. ( Chan, KW; Chan, TM; Hao, WK; Lai, KN; Li, FK; Lui, SL; Tang, S, 1999) |
| "Changes of activity index (AI) of lupus nephritis, urinary protein (UP), plasma albumin (PA), blood lipid (BL) of the patients before and after treatment were observed and compared." | 2.69 | [Clinical observation on nephrotic syndrome of lupus nephritis treated with integrated traditional Chinese and Western Medicine]. ( Wu, K; Wu, Q; Ye, R, 1998) |
| "005), despite a significant reduction in mean prednisone dosage (31 +/- 5 to 14 +/- 2 mg/day; p less than 0." | 2.66 | Intermittent intravenous cyclophosphamide therapy for lupus nephritis. ( Emery, HM; Kovalesky, A; Lehman, TJ; Magilavy, DB; McCurdy, DK; Sherry, DD; Wagner-Weiner, L, 1989) |
| "Lupus nephritis was present in two cases." | 2.49 | [Three cases of bullous lupus erythematosus]. ( Elomri, N; Elqatni, M; Ghafir, D; Jira, M; Mekouar, F; Sekkach, Y, 2013) |
| "The best therapeutic choice in lupus nephritis remains shrouded in a body of controversial literature." | 2.40 | Treatment of lupus nephritis: a meta-analysis of clinical trials. ( Bansal, VK; Beto, JA, 1997) |
| "Transformations from one pattern of lupus nephritis to another may occur, and there may also be prominent involvement of the tubulointerstitial compartment and vasculature." | 2.39 | The course and treatment of lupus nephritis. ( Appel, GB; Valeri, A, 1994) |
| " The corticosteroid dosage was gradually tapered." | 2.39 | Predominant tubulointerstitial lupus nephritis. ( Madias, NE; Singh, AK; Ucci, A, 1996) |
| "Prior to 1975 patients with systemic lupus erythematosus were generally not considered candidates for renal transplantation because of concern that immune complex deposition would rapidly destroy the allograft." | 2.38 | Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature. ( Cole, BR; Goss, JA; Hanto, DW; Jendrisak, MD; McCullough, CS; So, SK; Windus, DW, 1991) |
| " The LR treatment group received LR at the dosage of 1." | 1.91 | Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy. ( Fan, J; Guo, J; Huang, X; Liu, R; Peng, Y; Wu, H; Wu, M; Yang, X; Ye, H, 2023) |
| "028) and prednisone dosage during pregnancy ≥12." | 1.72 | Good pregnancy outcomes in lupus nephritis patients with complete renal remission. ( Chen, D; Chen, Y; Hu, W; Li, K; Liu, Z; Yang, L; Zhang, H, 2022) |
| "Renal biopsy revealed nodular glomerulosclerosis and FSGS." | 1.62 | Lupus podocytopathy superimposed on diabetic glomerulosclerosis: A case report. ( Liu, L; Murray, B; Tomaszewski, JE, 2021) |
| "An important goal in the management of systemic lupus erythematosus (SLE) is the prediction of relapses." | 1.56 | Anti-nucleosome antibodies increase the risk of renal relapse in a prospective cohort of patients with clinically inactive systemic lupus erythematosus. ( Alcaraz-Lopez, MF; Bonilla-Lara, D; Diaz-Rizo, V; Fajardo-Robledo, NS; Gamez-Nava, JI; Gonzalez-Lopez, L; Muñoz-Valle, JF; Perez-Guerrero, EE; Rodriguez-Jimenez, NA; Saldaña-Cruz, AM; Sanchez-Mosco, DI, 2020) |
| "Five hundred and two patients with systemic lupus erythematosus patients were included; 120 patients (23." | 1.56 | Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). ( Alarcón, GS; Alvarellos, A; Amigo, MC; Barile-Fabris, LA; Berbotto, GA; Bonfa, E; Borba Neto, EF; Caeiro, F; Cardiel, MH; Catoggio, LJ; Cavalcanti, F; Chacón-Diaz, R; Da Silva, NA; de Oliveira E Silva Montandon, AC; Esteva-Spinetti, MH; Garcia de la Torre, I; García, MA; Guibert-Toledano, M; Harvey, GB; Massardo, L; Neira, OJ; Pons-Estel, BA; Pons-Estel, GJ; Portela-Hernández, M; Quintana, R; Reátegui-Sokolova, C; Reyes-Llerena, GA; Sacnun, MP; Sato, EI; Saurit, V; Segami, MI; Serrano-Morales, RM; Silveira, LH; Soriano, ER; Ugarte-Gil, MF; Vásquez, G; Wojdyla, D, 2020) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| "The BC followed international lupus nephritis guidelines, combining high-dose prednisone and either mycophenolate mofetil or cyclophosphamide, followed by maintenance therapy with low dose prednisone and immunosuppressive drugs." | 1.46 | Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. ( Blanco, P; Couzi, L; Iza, A; Lazaro, E; Porta, S; Richez, C; Ruiz-Irastorza, G; Saenz, R; Saint-Pastou Terrier, C; Ugarte, A, 2017) |
| "Children with lupus nephritis have comparable or better cognitive function than their peers with other gCKDs, which is reassuring given the multiorgan and lifelong complications associated with lupus." | 1.46 | Cognitive Function in Children with Lupus Nephritis: A Cross-Sectional Comparison with Children with Other Glomerular Chronic Kidney Diseases. ( Furth, SL; Hooper, SR; Knight, A; Kogon, AJ; Matheson, MB; Warady, BA, 2017) |
| " The aim of this study was to investigate the efficacy and safety of bortezomib combined with glucocorticoids in refractory lupus patients." | 1.46 | The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis. ( Hou, J; Hu, W; Huang, L; Huang, X; Liu, Z; Zhang, H; Zhou, M, 2017) |
| " An effective and safe alternative induction regimen is needed." | 1.46 | Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. ( Babu, BG; Basu, B; Roy, B, 2017) |
| "Active lupus nephritis is a predictor for poor outcomes of pregnancies in SLE patients." | 1.43 | [Analysis of pregnancy outcomes in 66 patients with systemic lupus erythematosus]. ( Chen, JM; Song, XZ; Zhou, QG, 2016) |
| "The mean age at lupus nephritis presentation was 12." | 1.42 | Lupus nephritis in Croatian children: clinicopathologic findings and outcome. ( Batinić, D; Čorić, M; Jelušić, M; Milošević, D; Topalović-Grković, M; Turudić, D, 2015) |
| "Proteinuria was 2." | 1.38 | The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy. ( Bob, F; Bozdog, G; Cioca, D; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Marian, R; Petrica, L; Velciov, S; Vernic, C, 2012) |
| "Compared with pregnant women without lupus nephritis (n = 60), pregnancies with previous lupus nephritis (n = 35) were associated with a higher risk of maternal complications (88." | 1.38 | Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. ( Arias-Flores, R; Cruz-Cruz, P; Cruz-Reyes, C; Jara, LJ; Romero, GT; Saavedra, MA; Vera-Lastra, O, 2012) |
| "01) and dosage of immunosuppressant." | 1.38 | APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. ( Avihingsanon, Y; Benjachat, T; Eiam-ong, S; Hirankarn, N; Kittikowit, W; Leelahavanichkul, A; Somparn, P; Tantivitayakul, P; Treamtrakanpon, W, 2012) |
| "The treatment of membranous lupus nephritis (MLN) is still controversial in the literature." | 1.37 | Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis. ( Alves de Brito, G; Bitencourt Dias, C; Dos Santos Silva, V; Gera Abrão, J; Malafronte, P; Pinheiro, CC; Titan, S; Toledo Barros, R; Woronik, V, 2011) |
| " Most adverse events were transient and did not require change in therapy." | 1.35 | The effectiveness and safety of mycophenolate mofetil in lupus nephritis. ( Ballou, S; Elyan, M, 2009) |
| "Maintenance therapy of severe pediatric systemic lupus erythematosus (SLE) usually consists of azathioprine and prednisone ." | 1.35 | Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus. ( Amann, K; Benz, K; Dittrich, K; Dötsch, J; Ross, S, 2009) |
| "Patients with systemic lupus erythematosus (SLE) often produce autoantibodies against a large number of antigens." | 1.33 | Isaacs' syndrome (autoimmune neuromyotonia) in a patient with systemic lupus erythematosus. ( Taylor, PW, 2005) |
| "Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with systemic lupus erythematosus, as well as in adults." | 1.32 | Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. ( Lindsley, CB; Samad, AS, 2003) |
| " Patients with carotid abnormalities were significantly older, had higher blood pressure and total serum cholesterol levels, and had taken a higher prednisone cumulative dosage than those without any lesions." | 1.32 | Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. ( Corbanese, S; Doria, A; Favaretto, E; Gambari, PF; Ghirardello, A; Gilburd, B; Iaccarino, L; Patnaik, M; Pauletto, P; Peter, JB; Puato, M; Sherer, Y; Shoenfeld, Y; Todesco, S; Wu, R; Zampieri, S, 2003) |
| "In the immunosuppressive treatment of lupus nephritis the insertion of a consolidation phase with rituximab combined with cyclophosphamide achieves a therapeutically important and lasting deletion of the lymphocyte clone responsible for autoimmunity." | 1.32 | Remission of refractory lupus nephritis with a protocol including rituximab. ( Avanzi, GC; Bartoli, E; Fra, GP, 2003) |
| " CsA was given at a starting dosage of 5 mg x kg(-1) x d(-1) for 3 months, with a 1 mg x kg(-1) x d(-1) reduction every month and then maintained at a dosage of 2 mg x kg(-1) x d(-1)." | 1.32 | Cyclosporine A in treatment of membranous lupus nephropathy. ( Chen, H; Hu, W; Li, L; Li, S; Liu, Z; Shen, S; Yao, X, 2003) |
| "Nine patients with diffuse proliferative lupus nephritis confirmed by renal biopsy received MMF/prednisone for six months when repeat biopsies were performed." | 1.32 | Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study. ( Ding, L; Liu, Y; Wang, H; Zhao, M; Zou, W, 2004) |
| "Acquired ichthyosis is an uncommon disease, it is characterized by symmetric scaling of the skin, which ranges from minor roughness and dryness to the desquamation of large plaques." | 1.32 | Acquired ichthyosis associated with systemic lupus erythematosus. ( Guevara-Gutiérrez, E; Salazar-Páramo, M; Tlacuilo-Parra, JA, 2004) |
| "Azathioprine (AZA) was given as maintenance therapy in 117 patients (75%)." | 1.32 | Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. ( Lau, CS; Lee, KW; Leung, CY; Mok, CC; Ng, WL; Tang, S; Wong, RW; Ying, KY, 2004) |
| " The initial dosage of MMF was 0." | 1.31 | Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. ( Li, L; Lin, S; Wang, H, 2002) |
| "In the glomerulonephritides of systemic lupus erythematosus (SLE), the number of subendothelial deposits, when present, generally corresponds to the degree of light microscopic glomerular hypercellularity; only very rarely are no or few such deposits present in cases of focal (WHO class III) or diffuse (WHO class IV) proliferative lupus nephritis." | 1.31 | "Pauci-Immune" proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome. ( Charney, DA; Nadasdy, T; Nassar, G; Truong, L, 2000) |
| "To investigate the prognosis of lupus nephritis (LN) and its influencing factors in patients with lupus nephritis in China." | 1.30 | The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases. ( Li, L; Liu, Z; Shen, K; Tang, Z; Yu, Y, 1997) |
| "Mean proteinuria was 9 g/day with a mean duration of disease of 25 months (range 12-48)." | 1.30 | A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. ( Austin, HA; Balow, JE; Boumpas, DT; Fleisher, TA; Kim, Y; Piscitelli, S; Pucino, F; Tassiulas, IO; Vaughan, E, 1999) |
| "Patients with lupus nephritis frequently exhibit increasing proteinuria, hypertension and deterioration of renal function due to either active lupus nephritis, chronic lupus nephritis and/or superimposed preeclampsia during pregnancy." | 1.29 | Evaluation of lupus nephritis during pregnancy by renal biopsy. ( Krane, NK; Meleg-Smith, S; Thakur, V; Wood, H, 1995) |
| "21 patients with severe active lupus nephritis (LN) were treated with intravenous cyclophosphamide monthly doses 0." | 1.29 | [Monthly intravenous cyclophosphamide in the treatment of lupus nephritis]. ( Czyz, W; Klinger, M; Rychlewska, B, 1994) |
| "The data show that patients with ESRD secondary to lupus nephritis can undergo renal transplantation with satisfactory outcome." | 1.29 | Renal transplantation in systemic lupus erythematosus: a single-center experience with sixty-four cases. ( Aswad, S; Bangsil, R; el-Shahawy, MA; Massry, SG; Mendez, R; Mendez, RG, 1995) |
| "We report a 49 years old woman with systemic lupus erythematosus and a WHO type IV nephropathy, treated with prednisone 1 mg/kg/day po and cyclophosphamide 1 g/month iv." | 1.29 | [Lupus erythematosus disseminatus and Pneumocystis carinii pneumonia]. ( Guzmán, L; Neira, O; Wainstein, E, 1993) |
| "End-stage renal disease (ESRD) is one of the most significant complications of systemic lupus erythematosus (SLE)." | 1.29 | Treatment of end-stage renal disease due to lupus nephritis: comparison of six patients treated with both peritoneal and hemodialysis. ( Krane, NK; Stock, GG, 1993) |
| "Among children with lupus nephritis, those with Class IV disease, hypertension, high creatinine levels, and low C3 complement levels at the time of diagnosis are at increased risk for ESRD." | 1.29 | Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. ( Ahmad, H; Balachandra, S; Baqi, N; Moazami, S; Singh, A; Tejani, A, 1996) |
| "Most frequent are preeclampsia, premature labour, foetal maldevelopment and flare-ups of the underlying disease." | 1.28 | [Systemic lupus erythematosus and pregnancy. Clinical aspects, serology and management]. ( DuBois, A; Hillemanns, HG; Kerl, J; Quaas, L; Röther, E; Runge, HM, 1990) |
| "In 177 patients with lupus nephritis in the course of three decades three methods of immunotherapy were used the effect of which was evaluated retrospectively." | 1.28 | [Evaluation of long-term immunotherapy in patients with lupus nephritis]. ( Lukác, J; Rovenský, J; Zitnan, D, 1989) |
| " Twenty-five of 39 patients had normal complement levels within six months (Group 1), and immunosuppressive therapy was tapered but continuously readjusted to the lowest dosage that preserved normal CH50 and maintained clinical remission." | 1.28 | Effect of long-term normalization of serum complement levels on the course of lupus nephritis. ( Bank, N; Barland, P; Glicklich, D; Grayzel, AI; Laitman, RS; Sablay, LB, 1989) |
| "Six of 9 patients with ESRD and SLE died with active SLE and/or sepsis 1-28 months following the onset of dialysis." | 1.28 | Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares. ( Adler, SG; Cohen, AH; Louie, JS; Sires, RL, 1989) |
| "Treatment of lupus nephritis with high dose prednisone alone or in combination with immunosuppressants did not result in differences in patient survival or renal function preservation." | 1.28 | Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. ( Bronsveld, W; Nossent, JC; Swaak, AJ, 1989) |
| "We describe a patient who developed acute nonlymphocytic leukemia after receiving a total dose of 4 gm of cyclophosphamide over a 1-year period." | 1.27 | Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. ( Gibbons, RB; Westerman, E, 1988) |
| "Prednisone was discontinued in only one patient at any time during peritoneal dialysis." | 1.27 | Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis. ( Korbet, SM; Lewis, EJ; Rodby, RA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (11.79) | 18.7374 |
| 1990's | 60 (28.30) | 18.2507 |
| 2000's | 51 (24.06) | 29.6817 |
| 2010's | 58 (27.36) | 24.3611 |
| 2020's | 18 (8.49) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Li, K | 1 |
| Zhang, H | 4 |
| Liu, Z | 14 |
| Chen, D | 1 |
| Yang, L | 1 |
| Hu, W | 5 |
| Liu, L | 1 |
| Murray, B | 1 |
| Tomaszewski, JE | 1 |
| Cao, H | 1 |
| Liang, J | 1 |
| Liu, J | 2 |
| He, Y | 4 |
| Ke, Y | 1 |
| Sun, Y | 1 |
| Jiang, S | 1 |
| Lin, J | 1 |
| Fu, Q | 1 |
| Wu, C | 1 |
| Dai, M | 1 |
| Wang, S | 2 |
| Xu, J | 1 |
| Dai, L | 1 |
| Li, Z | 2 |
| He, L | 1 |
| Zhu, X | 1 |
| Sun, L | 2 |
| Lu, L | 1 |
| Bao, C | 1 |
| Du, L | 1 |
| Feng, Y | 1 |
| Wang, C | 2 |
| Shi, X | 1 |
| Wen, C | 1 |
| He, Z | 1 |
| Zhang, Y | 1 |
| Usiskin, IM | 1 |
| Kyttaris, VC | 2 |
| Liu, R | 1 |
| Huang, X | 2 |
| Ye, H | 1 |
| Wu, H | 1 |
| Guo, J | 1 |
| Peng, Y | 1 |
| Wu, M | 1 |
| Fan, J | 1 |
| Yang, X | 3 |
| Chang, JC | 1 |
| Varghese, SA | 1 |
| Behrens, EM | 1 |
| Gmuca, S | 1 |
| Kennedy, JS | 1 |
| Liebling, EJ | 1 |
| Lerman, MA | 1 |
| Mehta, JJ | 1 |
| Rutstein, BH | 1 |
| Sherry, DD | 2 |
| Stingl, CJ | 1 |
| Weaver, LK | 1 |
| Weiss, PF | 1 |
| Burnham, JM | 1 |
| Shi, Y | 1 |
| Yao, W | 1 |
| Li, G | 1 |
| Liu, H | 1 |
| Ding, P | 1 |
| Xu, H | 2 |
| Chen, J | 6 |
| Chen, P | 1 |
| Arpali, E | 1 |
| Akyollu, B | 1 |
| Yelken, B | 1 |
| Tekin, S | 1 |
| Turkmen, A | 1 |
| Kocak, B | 1 |
| Prasad, N | 1 |
| Kurian, J | 1 |
| Agarwal, V | 1 |
| Bhadauria, D | 1 |
| Behera, M | 1 |
| Yacha, M | 1 |
| Kushwaha, R | 1 |
| Agrawal, V | 1 |
| Jain, M | 1 |
| Gupta, A | 1 |
| Romano-Aguilar, M | 1 |
| Reséndiz-Galván, JE | 1 |
| Medellín-Garibay, SE | 1 |
| Milán-Segovia, RDC | 1 |
| Martínez-Martínez, MU | 1 |
| Abud-Mendoza, C | 1 |
| Romano-Moreno, S | 1 |
| Rodriguez-Jimenez, NA | 1 |
| Perez-Guerrero, EE | 1 |
| Gamez-Nava, JI | 1 |
| Sanchez-Mosco, DI | 1 |
| Saldaña-Cruz, AM | 1 |
| Alcaraz-Lopez, MF | 1 |
| Fajardo-Robledo, NS | 1 |
| Muñoz-Valle, JF | 1 |
| Bonilla-Lara, D | 1 |
| Diaz-Rizo, V | 1 |
| Gonzalez-Lopez, L | 1 |
| Fayed, A | 1 |
| El Menyawi, MM | 1 |
| Ghanema, M | 1 |
| Shaker, O | 1 |
| Elgohary, R | 1 |
| Reátegui-Sokolova, C | 1 |
| Ugarte-Gil, MF | 1 |
| Harvey, GB | 1 |
| Wojdyla, D | 1 |
| Pons-Estel, GJ | 1 |
| Quintana, R | 1 |
| Serrano-Morales, RM | 1 |
| Sacnun, MP | 1 |
| Catoggio, LJ | 1 |
| Soriano, ER | 1 |
| García, MA | 1 |
| Saurit, V | 1 |
| Alvarellos, A | 1 |
| Caeiro, F | 1 |
| Berbotto, GA | 1 |
| Sato, EI | 1 |
| Borba Neto, EF | 1 |
| Bonfa, E | 3 |
| de Oliveira E Silva Montandon, AC | 1 |
| Da Silva, NA | 1 |
| Cavalcanti, F | 1 |
| Vásquez, G | 1 |
| Guibert-Toledano, M | 1 |
| Reyes-Llerena, GA | 1 |
| Massardo, L | 1 |
| Neira, OJ | 1 |
| Cardiel, MH | 1 |
| Barile-Fabris, LA | 1 |
| Amigo, MC | 1 |
| Silveira, LH | 1 |
| Portela-Hernández, M | 1 |
| Garcia de la Torre, I | 1 |
| Segami, MI | 1 |
| Chacón-Diaz, R | 1 |
| Esteva-Spinetti, MH | 1 |
| Alarcón, GS | 1 |
| Pons-Estel, BA | 1 |
| Tselios, K | 1 |
| Gladman, DD | 1 |
| Al-Sheikh, H | 1 |
| Su, J | 1 |
| Urowitz, MB | 1 |
| Zen, M | 1 |
| Fuzzi, E | 1 |
| Loredo Martinez, M | 1 |
| Depascale, R | 1 |
| Fredi, M | 1 |
| Gatto, M | 1 |
| Larosa, M | 1 |
| Saccon, F | 1 |
| Iaccarino, L | 2 |
| Doria, A | 5 |
| Chavatza, K | 1 |
| Kostopoulou, M | 1 |
| Nikolopoulos, D | 1 |
| Gioti, O | 1 |
| Togia, K | 1 |
| Andreoli, L | 1 |
| Aringer, M | 1 |
| Boletis, J | 1 |
| Houssiau, FA | 1 |
| Jayne, D | 2 |
| Mosca, M | 2 |
| Svenungsson, E | 1 |
| Tincani, A | 1 |
| Bertsias, G | 1 |
| Fanouriakis, A | 1 |
| Boumpas, DT | 3 |
| Bomback, AS | 1 |
| Ruiz-Irastorza, G | 2 |
| Ugarte, A | 1 |
| Saint-Pastou Terrier, C | 1 |
| Lazaro, E | 1 |
| Iza, A | 1 |
| Couzi, L | 1 |
| Saenz, R | 1 |
| Richez, C | 1 |
| Porta, S | 1 |
| Blanco, P | 1 |
| Knight, A | 1 |
| Kogon, AJ | 1 |
| Matheson, MB | 1 |
| Warady, BA | 1 |
| Furth, SL | 1 |
| Hooper, SR | 1 |
| Zhou, M | 4 |
| Xing, C | 3 |
| Lin, H | 2 |
| Ni, Z | 3 |
| Fu, P | 3 |
| Liu, F | 3 |
| Chen, N | 2 |
| Zeng, C | 2 |
| Fu, J | 2 |
| Wang, Z | 3 |
| Lee, K | 1 |
| Wei, C | 1 |
| Zhang, M | 2 |
| Cai, M | 1 |
| Zhang, W | 1 |
| Chuang, PY | 1 |
| Ma'ayan, A | 1 |
| He, JC | 1 |
| Chen, WL | 1 |
| Liu, YD | 1 |
| Li, XL | 1 |
| Feng, SX | 1 |
| Zhou, XY | 1 |
| Ma, WX | 1 |
| Li, Y | 2 |
| Ye, DS | 1 |
| Chen, X | 1 |
| Chen, SL | 1 |
| Karasawa, K | 1 |
| Uchida, K | 1 |
| Takabe, T | 1 |
| Moriyama, T | 1 |
| Nitta, K | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 2 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| Castro, M | 1 |
| Ugolini-Lopes, M | 1 |
| Borba, EF | 2 |
| Seguro, LPC | 1 |
| Qi, C | 1 |
| Zha, Y | 1 |
| Luo, P | 1 |
| Wang, L | 1 |
| Sun, Z | 1 |
| Wan, J | 1 |
| Jiang, G | 1 |
| Sun, M | 1 |
| Chen, Q | 1 |
| Li, D | 1 |
| Guan, T | 1 |
| Fangtham, M | 1 |
| Petri, M | 5 |
| Danza, A | 1 |
| Perales, I | 1 |
| Villar, I | 1 |
| Garcia, M | 1 |
| Delgado, S | 1 |
| Khamashta, M | 1 |
| Jira, M | 1 |
| Elqatni, M | 1 |
| Sekkach, Y | 1 |
| Elomri, N | 1 |
| Mekouar, F | 1 |
| Ghafir, D | 1 |
| Tian, SY | 2 |
| Feldman, BM | 2 |
| Beyene, J | 2 |
| Brown, PE | 2 |
| Uleryk, EM | 2 |
| Silverman, ED | 2 |
| Watson, P | 1 |
| Brennan, A | 1 |
| Birch, H | 1 |
| Fang, H | 1 |
| Miao, L | 1 |
| Gu, Y | 1 |
| Shi, W | 1 |
| Bao, H | 3 |
| Arends, S | 1 |
| Berden, JH | 2 |
| Grootscholten, C | 1 |
| Derksen, RH | 2 |
| Berger, SP | 1 |
| de Sévaux, RG | 1 |
| Voskuyl, AE | 2 |
| Batinić, D | 1 |
| Milošević, D | 1 |
| Čorić, M | 1 |
| Topalović-Grković, M | 1 |
| Jelušić, M | 1 |
| Turudić, D | 1 |
| Cotton, D | 1 |
| Mahmoud, GA | 1 |
| Zayed, HS | 1 |
| Ghoniem, SA | 1 |
| Hu, WX | 2 |
| Chen, YH | 1 |
| Liu, ZZ | 1 |
| Wang, SF | 1 |
| Zhang, HT | 2 |
| Liu, ZH | 2 |
| Campise, M | 1 |
| Giglio, E | 1 |
| Trespidi, L | 1 |
| Messa, P | 1 |
| Moroni, G | 5 |
| Warren, CC | 1 |
| Gendy, MG | 1 |
| Kim, JE | 1 |
| Mejía-Vilet, JM | 1 |
| Córdova-Sánchez, BM | 1 |
| Uribe-Uribe, NO | 1 |
| Correa-Rotter, R | 1 |
| Staveri, C | 1 |
| Karokis, D | 1 |
| Liossis, SC | 1 |
| Tsang-A-Sjoe, MW | 1 |
| Bultink, IE | 1 |
| Heslinga, M | 1 |
| Song, XZ | 1 |
| Chen, JM | 1 |
| Zhou, QG | 1 |
| Huang, L | 1 |
| Hou, J | 1 |
| Al-Khazraji, A | 1 |
| Takher, J | 1 |
| Alkhawam, H | 1 |
| Fabbri, M | 1 |
| Basu, B | 1 |
| Roy, B | 1 |
| Babu, BG | 1 |
| Ataia, I | 1 |
| Casaulta, C | 1 |
| von Vigier, RO | 1 |
| Pfammatter, JP | 1 |
| Brekenfeld, C | 1 |
| Sauvain, MJ | 1 |
| Steinlin, M | 1 |
| Cohen, RA | 1 |
| Bayliss, G | 1 |
| Crispin, JC | 1 |
| Kane-Wanger, GF | 1 |
| Van Beek, CA | 1 |
| Avalos, I | 1 |
| Yu, CY | 1 |
| Tsokos, GC | 1 |
| Stillman, IE | 1 |
| Xie, HL | 1 |
| Li, LS | 1 |
| Ahmadzadeh, A | 2 |
| Derakhshan, A | 1 |
| Austin, HA | 3 |
| Illei, GG | 2 |
| Braun, MJ | 1 |
| Balow, JE | 3 |
| Elyan, M | 1 |
| Ballou, S | 1 |
| Yu, F | 1 |
| Tan, Y | 1 |
| Liu, G | 1 |
| Wang, SX | 1 |
| Zou, WZ | 1 |
| Zhao, MH | 1 |
| Radhakrishnan, J | 2 |
| Moutzouris, DA | 1 |
| Ginzler, EM | 5 |
| Solomons, N | 3 |
| Siempos, II | 1 |
| Appel, GB | 5 |
| Isenberg, D | 2 |
| Contreras, G | 3 |
| Dooley, MA | 3 |
| Sánchez-Guerrero, J | 1 |
| Wofsy, D | 2 |
| Yu, X | 4 |
| Dittrich, K | 1 |
| Ross, S | 1 |
| Benz, K | 1 |
| Amann, K | 1 |
| Dötsch, J | 1 |
| Gordon, C | 1 |
| Lisk, L | 2 |
| Gluhovschi, C | 2 |
| Gluhovschi, G | 2 |
| Herman, D | 1 |
| Trandafirescu, V | 1 |
| Petrica, L | 2 |
| Velciov, S | 2 |
| Bozdog, G | 2 |
| Bob, F | 2 |
| Cioca, D | 2 |
| Patel, SB | 1 |
| Korbet, SM | 3 |
| Lewis, EJ | 8 |
| Chen, W | 4 |
| Tang, X | 1 |
| Liu, Q | 1 |
| Liao, Y | 1 |
| Yang, Z | 1 |
| Zhang, J | 2 |
| Lou, T | 1 |
| Kong, Y | 1 |
| Fan, A | 1 |
| Rao, S | 1 |
| Kendouci-Tani, MS | 1 |
| Talet, HB | 1 |
| Sekkal, A | 1 |
| Heras, M | 1 |
| Saiz, A | 1 |
| Fernández-Reyes, MJ | 1 |
| Sánchez, R | 1 |
| Zurita, P | 1 |
| Urrego, C | 1 |
| Wu, XL | 2 |
| Zhang, WG | 1 |
| Shi, XM | 2 |
| An, P | 2 |
| Sun, WS | 2 |
| Qiao, CL | 2 |
| Kaycsa, A | 1 |
| Marian, R | 1 |
| Gadalean, F | 1 |
| Vernic, C | 1 |
| Bitencourt Dias, C | 1 |
| Pinheiro, CC | 1 |
| Malafronte, P | 1 |
| Titan, S | 1 |
| Alves de Brito, G | 1 |
| Gera Abrão, J | 1 |
| Dos Santos Silva, V | 1 |
| Toledo Barros, R | 1 |
| Woronik, V | 1 |
| Carneiro, FO | 1 |
| Sampaio, LR | 1 |
| Brandão, LA | 1 |
| Braga, LL | 1 |
| Rocha, FA | 1 |
| Paliga, A | 1 |
| Shahbazi, N | 1 |
| Gonsalves, C | 1 |
| Bormanis, J | 1 |
| Padmore, R | 1 |
| Pinto Valdivia, M | 1 |
| Samson, M | 1 |
| Audia, S | 1 |
| Leguy, V | 1 |
| Berthier, S | 1 |
| Janikashvili, N | 1 |
| Martin, L | 1 |
| Bonnotte, B | 1 |
| Lorcerie, B | 1 |
| Saavedra, MA | 1 |
| Cruz-Reyes, C | 1 |
| Vera-Lastra, O | 1 |
| Romero, GT | 1 |
| Cruz-Cruz, P | 1 |
| Arias-Flores, R | 1 |
| Jara, LJ | 1 |
| Wax, S | 1 |
| Rajeswaran, A | 1 |
| Copt, S | 1 |
| Hillson, J | 1 |
| Ramos, E | 1 |
| Singer, NG | 1 |
| Rubio-Rivas, M | 1 |
| Gómez-Junyent, J | 1 |
| Simonetti, A | 1 |
| Mitjavila, F | 1 |
| Capdevila, O | 1 |
| Pujol, R | 1 |
| Rivera, F | 2 |
| Fulladosa, X | 1 |
| Poveda, R | 1 |
| Frutos, MA | 1 |
| García-Frías, P | 1 |
| Ara, J | 1 |
| Illescas, L | 1 |
| López-Rubio, E | 1 |
| Mérida, E | 1 |
| Carreño, A | 2 |
| Ballarín, J | 1 |
| Fernández-Juárez, G | 1 |
| Baltar, J | 1 |
| Ramos, C | 1 |
| Pons, S | 1 |
| Oliet, A | 1 |
| Vigil, A | 1 |
| Praga, M | 1 |
| Segarra, A | 1 |
| Redondo-Pachón, MD | 1 |
| Enríquez, R | 2 |
| Sirvent, AE | 1 |
| Andrada, E | 1 |
| Millán, I | 1 |
| Amorós, F | 2 |
| Sundel, R | 1 |
| Fischer-Betz, R | 1 |
| Chehab, G | 1 |
| Sander, O | 1 |
| Vordenbäumen, S | 1 |
| Voiculescu, A | 1 |
| Brinks, R | 1 |
| Schneider, M | 1 |
| Treamtrakanpon, W | 1 |
| Tantivitayakul, P | 1 |
| Benjachat, T | 1 |
| Somparn, P | 1 |
| Kittikowit, W | 1 |
| Eiam-ong, S | 1 |
| Leelahavanichkul, A | 1 |
| Hirankarn, N | 1 |
| Avihingsanon, Y | 1 |
| Ayodele, OE | 1 |
| Okpechi, IG | 1 |
| Swanepoel, CR | 1 |
| Li, L | 3 |
| Wang, H | 3 |
| Lin, S | 1 |
| Lavina, AM | 1 |
| Agarwal, A | 1 |
| Hunyor, A | 1 |
| Gass, JD | 1 |
| Samad, AS | 1 |
| Lindsley, CB | 1 |
| POLLAK, VE | 3 |
| KARK, RM | 2 |
| PIRANI, CL | 2 |
| WILSON, RM | 1 |
| MAHER, JF | 1 |
| SCHREINER, GE | 1 |
| SMITH, FG | 1 |
| LITMAN, N | 1 |
| LATTA, H | 1 |
| Shoenfeld, Y | 2 |
| Wu, R | 1 |
| Gambari, PF | 1 |
| Puato, M | 1 |
| Ghirardello, A | 1 |
| Gilburd, B | 1 |
| Corbanese, S | 1 |
| Patnaik, M | 1 |
| Zampieri, S | 1 |
| Peter, JB | 1 |
| Favaretto, E | 1 |
| Sherer, Y | 2 |
| Todesco, S | 2 |
| Pauletto, P | 1 |
| Fra, GP | 1 |
| Avanzi, GC | 1 |
| Bartoli, E | 1 |
| Utiger, RD | 1 |
| Galindo-Rodríguez, G | 1 |
| Bustamante, R | 1 |
| Esquivel-Nava, G | 1 |
| Salazar-Exaire, D | 1 |
| Vela-Ojeda, J | 1 |
| Vadillo-Buenfil, M | 1 |
| Aviña-Zubieta, JA | 1 |
| Shen, S | 1 |
| Li, S | 1 |
| Yao, X | 1 |
| Chen, H | 1 |
| Mok, CC | 2 |
| Ying, KY | 2 |
| Lau, CS | 2 |
| Yim, CW | 1 |
| Ng, WL | 2 |
| Wong, WS | 1 |
| Au, TC | 1 |
| Lehman, TJ | 2 |
| Edelheit, BS | 1 |
| Onel, KB | 1 |
| Ding, L | 1 |
| Zhao, M | 1 |
| Zou, W | 1 |
| Liu, Y | 3 |
| Pardo, V | 1 |
| Leclercq, B | 1 |
| Lenz, O | 1 |
| Tozman, E | 2 |
| O'Nan, P | 1 |
| Roth, D | 1 |
| Zappitelli, M | 1 |
| Duffy, C | 1 |
| Bernard, C | 1 |
| Scuccimarri, R | 1 |
| Watanabe Duffy, K | 1 |
| Kagan, R | 1 |
| Gupta, IR | 1 |
| Liang, L | 2 |
| Zhan, Z | 2 |
| Ye, Y | 2 |
| Tlacuilo-Parra, JA | 1 |
| Guevara-Gutiérrez, E | 1 |
| Salazar-Páramo, M | 1 |
| Farhey, Y | 1 |
| Hess, E | 1 |
| Tang, S | 2 |
| Leung, CY | 1 |
| Lee, KW | 1 |
| Wong, RW | 1 |
| Taylor, PW | 1 |
| Nahar, N | 1 |
| Metz, D | 1 |
| Hauser, AC | 1 |
| Hauser, L | 1 |
| Pabinger-Fasching, I | 1 |
| Quehenberger, P | 1 |
| Derfler, K | 1 |
| Hörl, WH | 1 |
| Aranow, C | 1 |
| Kim, MY | 1 |
| Buyon, J | 1 |
| Merrill, JT | 1 |
| Gilkeson, GS | 1 |
| Wallace, DJ | 3 |
| Weisman, MH | 1 |
| Zheng, WC | 1 |
| Hu, SJ | 1 |
| Fang, Q | 1 |
| Ozkan, HA | 1 |
| Ozkalemkas, F | 1 |
| Ali, R | 1 |
| Ozkocaman, V | 1 |
| Ozcelik, T | 1 |
| Sánchez de la Nieta, MD | 1 |
| de la Torre, M | 1 |
| Kasitanon, N | 1 |
| Fine, DM | 1 |
| Haas, M | 1 |
| Magder, LS | 1 |
| Mittal, BV | 1 |
| Pendse, S | 1 |
| Rennke, HG | 1 |
| Singh, AK | 3 |
| Burchardi, C | 1 |
| Schlöndorff, D | 1 |
| Wang, YH | 1 |
| Wu, XX | 1 |
| Tan, JP | 1 |
| Zhang, JP | 1 |
| Chan, TM | 2 |
| Cavallasca, JA | 1 |
| Laborde, HA | 1 |
| Ruda-Vega, H | 1 |
| Nasswetter, GG | 1 |
| Zar, T | 1 |
| Samson, W | 1 |
| Palmisano, J | 1 |
| Alberighi, OD | 1 |
| Ferraccioli, G | 1 |
| Manno, C | 1 |
| Altieri, P | 1 |
| Ferrara, R | 1 |
| Greco, S | 1 |
| Ponticelli, C | 4 |
| de Groot, K | 1 |
| Schwartz, MM | 3 |
| Krane, NK | 2 |
| Thakur, V | 1 |
| Wood, H | 1 |
| Meleg-Smith, S | 1 |
| Remuzzi, G | 1 |
| Gotti, E | 1 |
| Klinger, M | 1 |
| Rychlewska, B | 1 |
| Czyz, W | 1 |
| el-Shahawy, MA | 1 |
| Aswad, S | 1 |
| Mendez, RG | 1 |
| Bangsil, R | 1 |
| Mendez, R | 1 |
| Massry, SG | 1 |
| Oberle, GP | 1 |
| Helmchen, U | 1 |
| Stahl, RA | 1 |
| van den Wall Bake, AW | 1 |
| de Glas-Vos, JW | 1 |
| Hagen, EC | 1 |
| Valeri, A | 2 |
| Estes, D | 1 |
| D'Agati, V | 1 |
| Kopelman, R | 1 |
| Pernis, A | 1 |
| Flis, R | 1 |
| Pirani, C | 1 |
| Piccoli, A | 1 |
| Vesco, P | 1 |
| Vaccaro, E | 1 |
| Marson, P | 1 |
| De Silvestro, G | 1 |
| Ossi, E | 1 |
| Gambari, P | 1 |
| Ye, RG | 1 |
| Ren, GH | 1 |
| Li, HQ | 1 |
| McInnes, PM | 1 |
| Schuttinga, J | 1 |
| Sanslone, WR | 1 |
| Stark, SP | 1 |
| Klippel, JH | 2 |
| Wainstein, E | 1 |
| Neira, O | 1 |
| Guzmán, L | 1 |
| Stock, GG | 1 |
| Bertoni, M | 1 |
| Brugnolo, F | 1 |
| Bertoni, E | 1 |
| Salvadori, M | 1 |
| Romagnani, S | 1 |
| Emmi, L | 1 |
| Santos, RD | 1 |
| Vinagre, CG | 1 |
| Pileggi, FJ | 1 |
| Cossermelli, W | 1 |
| Maranhão, RC | 1 |
| Fagundus, DM | 1 |
| Leroy, EC | 1 |
| Gandhi, R | 1 |
| Hussein, MM | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Ucci, A | 1 |
| Madias, NE | 1 |
| Baqi, N | 1 |
| Moazami, S | 1 |
| Singh, A | 1 |
| Ahmad, H | 1 |
| Balachandra, S | 1 |
| Tejani, A | 1 |
| Bansal, VK | 1 |
| Beto, JA | 1 |
| Cockwell, P | 1 |
| Asherson, RA | 1 |
| Schatten, S | 1 |
| Hughes, GR | 1 |
| Ware, AE | 1 |
| Mongey, AB | 1 |
| Matuszkiewicz-Rowińska, J | 2 |
| Ostrowski, K | 1 |
| Shen, K | 1 |
| Yu, Y | 1 |
| Tang, Z | 1 |
| Ye, R | 2 |
| Xie, C | 1 |
| Diouf, B | 1 |
| Toure, AO | 1 |
| Ka, MM | 1 |
| Pouye, A | 1 |
| Diop, TM | 1 |
| Lin, WY | 1 |
| Lan, JL | 1 |
| Wang, SJ | 1 |
| Jiang, Y | 1 |
| Huong, DL | 1 |
| Papo, T | 1 |
| Beaufils, H | 1 |
| Wechsler, B | 1 |
| Blétry, O | 1 |
| Baumelou, A | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Tassiulas, IO | 1 |
| Fleisher, TA | 1 |
| Vaughan, E | 1 |
| Piscitelli, S | 1 |
| Kim, Y | 1 |
| Pucino, F | 1 |
| Li, FK | 1 |
| Hao, WK | 1 |
| Chan, KW | 1 |
| Lui, SL | 1 |
| Lai, KN | 1 |
| Levy, Y | 1 |
| George, J | 1 |
| Rovensky, J | 2 |
| Lukac, J | 2 |
| Rauova, L | 1 |
| Poprac, P | 1 |
| Langevitz, P | 1 |
| Fabbrizzi, F | 1 |
| Charney, DA | 1 |
| Nassar, G | 1 |
| Truong, L | 1 |
| Nadasdy, T | 1 |
| Belmont, HM | 1 |
| Emre, S | 1 |
| Bilge, I | 1 |
| Sirin, A | 1 |
| Kilicaslan, I | 1 |
| Nayir, A | 1 |
| Oktem, F | 1 |
| Uysal, V | 1 |
| Wu, Q | 1 |
| Wu, K | 1 |
| Crane, M | 1 |
| Collins, L | 1 |
| Gourley, MF | 2 |
| Yarboro, CH | 1 |
| Vaughan, EM | 1 |
| Kuroiwa, T | 1 |
| Danning, CL | 1 |
| Steinberg, AD | 3 |
| Buratti, S | 1 |
| Szer, IS | 2 |
| Spencer, CH | 1 |
| Bartosh, S | 1 |
| Reiff, A | 1 |
| Tam, LS | 1 |
| Li, EK | 1 |
| Szeto, CC | 1 |
| Wong, SM | 1 |
| Leung, CB | 1 |
| Lai, FM | 1 |
| Wong, KC | 1 |
| Lui, SF | 1 |
| Yin, P | 1 |
| Ter Meulen, CG | 1 |
| Pieters, GF | 1 |
| Huysmans, FT | 1 |
| Lachin, JM | 3 |
| Lan, SP | 4 |
| Balletta, M | 1 |
| Sabella, D | 1 |
| Magri, P | 1 |
| Sepe, V | 1 |
| Stanziale, P | 1 |
| Di Luccio, R | 1 |
| Colucci, G | 1 |
| Fuiano, G | 1 |
| Banfi, G | 3 |
| Muir, J | 1 |
| Scott, DE | 1 |
| Robinson, JA | 1 |
| Zhuang, GK | 1 |
| Yuan, ZZ | 1 |
| Zhang, ZL | 1 |
| Qing, WZ | 1 |
| Jin, Y | 1 |
| Euler, HH | 1 |
| Schroeder, JO | 1 |
| Sesso, R | 1 |
| Klag, M | 1 |
| Lauzurica, R | 1 |
| Bonet, J | 1 |
| Vaquero, M | 1 |
| Torguet, P | 1 |
| Serra, A | 1 |
| Borrás, M | 1 |
| Caralps, A | 1 |
| Hunsicker, LG | 2 |
| Rohde, RD | 1 |
| Levey, AS | 1 |
| Corwin, HL | 1 |
| Kasinath, BS | 1 |
| Lachin, J | 1 |
| Neilson, EG | 1 |
| Ballati, G | 1 |
| Tucciarone, L | 1 |
| Diamanti, A | 1 |
| Frangella, E | 1 |
| Chiaramida, N | 1 |
| Steinberg, SC | 1 |
| Goss, JA | 1 |
| Cole, BR | 1 |
| Jendrisak, MD | 1 |
| McCullough, CS | 1 |
| So, SK | 1 |
| Windus, DW | 1 |
| Hanto, DW | 1 |
| Tovar, JV | 1 |
| Cabezuelo, JB | 1 |
| Gonzalez, C | 1 |
| Pohl, MA | 1 |
| Berl, T | 1 |
| Hahn, BH | 1 |
| Hariharan, S | 1 |
| Kant, KS | 1 |
| Weiss, MA | 1 |
| Wadhwa, NK | 1 |
| Escobar, A | 1 |
| Del Brutto, OH | 1 |
| Clough, JD | 1 |
| Runge, HM | 1 |
| Röther, E | 1 |
| Kerl, J | 1 |
| DuBois, A | 1 |
| Quaas, L | 1 |
| Hillemanns, HG | 1 |
| Bernstein, J | 1 |
| Hill, GS | 1 |
| Holley, K | 1 |
| Phillips, EA | 1 |
| Wagner-Weiner, L | 1 |
| McCurdy, DK | 1 |
| Emery, HM | 1 |
| Magilavy, DB | 1 |
| Kovalesky, A | 1 |
| Pozsonyi, T | 1 |
| Jakab, L | 1 |
| Síró, I | 1 |
| Potyondi, J | 1 |
| Zitnan, D | 1 |
| Laitman, RS | 1 |
| Glicklich, D | 1 |
| Sablay, LB | 1 |
| Grayzel, AI | 1 |
| Barland, P | 1 |
| Bank, N | 1 |
| Ostrov, BE | 1 |
| Min, W | 1 |
| Eichenfield, AH | 1 |
| Goldsmith, DP | 1 |
| Kaplan, B | 1 |
| Athreya, BH | 1 |
| Sires, RL | 1 |
| Adler, SG | 1 |
| Louie, JS | 1 |
| Cohen, AH | 1 |
| Nossent, JC | 1 |
| Bronsveld, W | 1 |
| Swaak, AJ | 1 |
| Gibbons, RB | 1 |
| Westerman, E | 1 |
| Stone, J | 1 |
| Smurra, G | 1 |
| Quaranta, G | 1 |
| Angiello, G | 1 |
| Zucchelli, P | 1 |
| Cagnoli, L | 1 |
| Pasquali, S | 1 |
| Walker, RJ | 1 |
| Bailey, RR | 1 |
| Swainson, CP | 1 |
| Lynn, KL | 1 |
| Rodby, RA | 1 |
| Dillard, MG | 1 |
| Kawala, K | 1 |
| Strober, S | 1 |
| Farinas, MC | 1 |
| Field, EH | 1 |
| Solovera, JJ | 1 |
| Kiberd, BA | 1 |
| Myers, BD | 1 |
| Hoppe, RT | 1 |
| Garin, EH | 1 |
| Sleasman, JW | 1 |
| Richard, GA | 1 |
| Iravani, AA | 1 |
| Fennell, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Multicenter Trial Comparing Leflunomide and Azathioprine as Remission-Maintaining Treatment for Proliferative Lupus Glomerulonephritis.[NCT01172002] | 200 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | |||
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone[NCT03187743] | 72 participants (Actual) | Interventional | 2018-04-17 | Completed | |||
| Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis[NCT04146220] | Phase 4 | 32 participants (Actual) | Interventional | 2018-07-16 | Completed | ||
| An Multi-site, Open, Prospective Study to Assess the Efficacy and Safety of Multi-target Therapy in the Treatment of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+Ⅴ Lupus Nephritis[NCT00876616] | 362 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| An Open, Prospective Study to Assess the Efficacy and Safety of FK506 Combined MMF in the Treatment of Class III，IV，V + IV or V + III Lupus Nephritis[NCT00298506] | 120 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| A Prospective, Randomized, Active Controlled, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Mycophenolate Mofetil (MMF) in Inducing Response and Maintaining Remission in Subjects With Lupus Nephritis.[NCT00377637] | Phase 3 | 370 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [NCT00615173] | Phase 3 | 81 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects With Lupus Nephritis in Combination With Mycophenolate Mofetil Therapy.[NCT00573157] | Phase 2/Phase 3 | 6 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to The study was terminated due to unanticipated safety issues) | ||
| Insulin Resistance and Atherosclerosis in a Sample of Women With Systemic Lupus Erythematosus[NCT00544102] | 50 participants (Actual) | Observational | 2007-10-11 | Completed | |||
| Treatment of Periodontal Disease in Systemic Lupus Erytematosus: A Pilot Randomized Controlled Clinical Trial[NCT04046172] | 200 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | |||
| A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy.[NCT00504244] | Phase 3 | 12 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to Insufficient recruitment) | ||
| Five-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intrav[NCT00336414] | Phase 3 | 0 participants (Actual) | Interventional | 2006-06-30 | Withdrawn (stopped due to the study is withdrawn due to low and unexpected enrollment rate) | ||
| CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid[NCT03492255] | 49 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Significative difference between percentage of renal response (primary outcome) between the two study arms.) | |||
| Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus[NCT02444728] | Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Because of insufficient enrollement) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment Failure was adjudicated by a clinical endpoints committee (CEC) and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis (LN). (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Deaths (Number) |
|---|---|
| Mycophenolate Mofetil (MMF) | 0 |
| Azathioprine (AZA) | 1 |
Time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), was defined as any 1 the following: death, ESRD, sustained doubling of serum creatinine, renal flare (proteinuric or nephritic), or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. ESRD is defined as progression to chronic hemodialysis or renal transplant. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil (MMF) | 0 |
| Azathioprine (AZA) | 3 |
Sustained doubling of serum creatinine concentration is defined as the first serum creatinine value that is twice the mean of the lowest 2 values from screening to end of induction, as confirmed by a second serum creatinine value obtained at least 4 weeks after the initial doubling. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil | 1 |
| Azathioprine | 5 |
A major extra-renal flare is defined as a British Isles Lupus Assessment Group (BILAG) Score category A in one extrarenal organ or three organs with concurrent category B scores. BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | participants (Number) |
|---|---|
| Mycophenolate Mofetil | 7 |
| Azathioprine | 6 |
The SF-36 is a 36 item quality of life questionnaire. The short-form version has eleven questions that permit the participant to rate how they feel that particular day. The SF-36 consists of eight scaled scores and two component scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 score with the higher scores indicating better quality of life. (NCT00377637)
Timeframe: Baseline and 24 weeks
| Intervention | Scores on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Physical Component Summary [n=139, 137] | Mental Component Summary [n=139, 137] | Bodily Pain Score [n=141, 137] | General Health Score [n=139, 137] | Mental Health Score [n=141, 137] | Physical functioning Score [n=141, 137] | Role-Emotional Score [n=141, 137] | Role-Physical Score [n=141, 137] | Social Function Score [n=141, 137] | Vitality Score [n=141, 137] | |
| Intravenous Cyclophosphamide | 6.4 | 5.7 | 16.8 | 11.5 | 9.8 | 9.3 | 18.4 | 34.0 | 18.2 | 11.6 |
| Mycophenolate Mofetil | 5.2 | 6.7 | 13.4 | 9.1 | 9.3 | 11.6 | 23.4 | 28.6 | 17.7 | 14.2 |
24-hour urine protein was measured at Baseline and Week 24. (NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | mg/day (Mean) | ||
|---|---|---|---|
| Baseline [n=180, 180] | Week 24 [n= 150, 144] | Change from Baseline to Week 24 [n= 146, 142] | |
| Intravenous Cyclophosphamide | 4451.4 | 1831.6 | -2513.7 |
| Mycophenolate Mofetil | 4208.9 | 1599.0 | -2510.6 |
(NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | g/L (Mean) | ||
|---|---|---|---|
| Baseline [n=184, 185] | Week 24 [n=155, 151] | Change from Baseline to Week 24 [n=154, 151] | |
| Intravenous Cyclophosphamide | 28.6 | 38.3 | 9.0 |
| Mycophenolate Mofetil | 30.5 | 38.4 | 7.5 |
(NCT00377637)
Timeframe: Baseline, Week 24
| Intervention | µmol/L (Mean) | ||
|---|---|---|---|
| Baseline [n= 184, 185] | Week 24 [n= 155, 151] | Change from Baseline to Week 24 [n= 154, 151] | |
| Intravenous Cyclophosphamide | 92.7 | 83.5 | -5.1 |
| Mycophenolate Mofetil | 108.6 | 77.6 | -18.9 |
"BILAG indices provide a scoring system for the assessment of lupus disease activity in terms of the need for steroid treatment in 8 organs/systems. Eighty-six items were scored resulting in a classification of A (severe activity), B (moderate activity), C (mild activity), D (no current activity) and E (no activity ever observed) for each organ system. The BILAG individual system summaries were calculated by a program supplied by ADS-Limathon (Sheffield, UK).~The score at baseline was compared to the score at the 24 week endpoint for each treatment group, reported here for the renal system." (NCT00377637)
Timeframe: Baseline, 24 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shift from Baseline=A to 24 Week Endpoint=A | Shift from Baseline=A to 24 Week Endpoint=B | Shift from Baseline=A to 24 Week Endpoint=C | Shift from Baseline=A to 24 Week Endpoint=D | Shift from Baseline=B to 24 Week Endpoint=A | Shift from Baseline=B to 24 Week Endpoint=B | Shift from Baseline=B to 24 Week Endpoint=C | Shift from Baseline=B to 24 Week Endpoint=D | Shift from Baseline=C to 24 Week Endpoint=A | Shift from Baseline=C to 24 Week Endpoint=B | Shift from Baseline=C to 24 Week Endpoint=C | Shift from Baseline=C to 24 Week Endpoint=D | Shift from Baseline=D to 24 Week Endpoint=A | Shift from Baseline=D to 24 Week Endpoint=B | Shift from Baseline=D to 24 Week Endpoint=C | Shift from Baseline=D to 24 Week Endpoint=D | |
| Intravenous Cyclophosphamide | 27.1 | 34.8 | 24.9 | 9.4 | 0.0 | 1.1 | 1.7 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 |
| Mycophenolate Mofetil | 17.1 | 39.2 | 33.1 | 5.5 | 0.0 | 1.7 | 2.2 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Number of participants achieving complete remission as defined by return to normal serum creatinine, proteinuria ≤500 mg/24 hours and an inactive urinary sediment (absence of red blood cells, white blood cells or cellular or granular casts) after 24 weeks. (NCT00377637)
Timeframe: 24 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Complete Remission - Yes | Complete Remission - No | |
| Intravenous Cyclophosphamide | 15 | 170 |
| Mycophenolate Mofetil | 16 | 169 |
Treatment response was adjudicated by a blinded clinical endpoints committee (CEC) and defined as: a) Decrease in proteinuria, defined as a decrease in the urine protein to creatinine ratio (UPCr) to <3 in subjects with baseline proteinuria ≥3 UPCr or a decrease in the UPCr by ≥50% in subjects with proteinuria <3 UPCr at Baseline, and b) Stabilization of serum creatinine or improvement. UPCr were derived from the 24 hour urine collection. Patients who did not show a treatment response at Week 24 or who withdrew earlier than Week 24 were considered non-responders. (NCT00377637)
Timeframe: 24 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non-responder | |
| Intravenous Cyclophosphamide | 98 | 87 |
| Mycophenolate Mofetil | 104 | 81 |
The primary efficacy parameter was the time to treatment failure, adjudicated by the Clinical Endpoints Committee (CEC), defined as any of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or requirement for rescue therapy to treat deterioration or exacerbation of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to rescue treatment for each patient. The data presented are the percentage of participants who were rescue treatment free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 99.1 | 95.1 | 93.0 | 91.9 | 88.4 | 87.1 | 83.1 | 83.1 | 81.7 | 80.3 | 78.8 | 75.9 |
| Mycophenolate Mofetil | 100 | 98.2 | 97.2 | 94.2 | 94.2 | 94.2 | 93.1 | 91.9 | 90.8 | 90.8 | 90.8 | 90.8 |
A proteinuric flare is defined as a doubling of the urine protein:creatinine ratio, and proteinuria ≥1 g/24 h in patients with urine protein ≤0.5 g/24 h at the end of the induction phase, or proteinuria ≥2 g/24 h if urine protein was >0.5 g/24 h at the end of the induction phase. A nephritic flare is defined as a 25% increase in serum creatinine accompanied by 1 or more of the following: (a) simultaneous doubling of the proteinuria reaching a minimum of 2 g/24 h (b) new/increased hematuria or (c) the appearance of cellular casts. All flares were adjudicated by a clinical endpoints committee. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 97.2 | 90.3 | 87.2 | 85.0 | 82.8 | 79.2 | 78.0 | 75.5 | 74.2 | 74.2 | 72.9 | 70.1 |
| Mycophenolate Mofetil | 98.2 | 94.6 | 90.8 | 87.8 | 87.8 | 86.8 | 86.8 | 86.8 | 86.8 | 86.8 | 85.6 | 85.6 |
Treatment Failure was adjudicated by a clinical endpoints committee and was defined as the time to the earliest occurrence of any one of the following: death, end stage renal disease, sustained doubling of serum creatinine, renal flare, or a requirement for rescue therapy for exacerbation or deterioration of Lupus nephritis. Kaplan-Meier survival curves were estimated from the observed time to treatment failure for each patient. The data presented are the percentage of participants who were treatment-failure free at each time interval as estimated by Kaplan-Meier. (NCT00377637)
Timeframe: From the start of the Maintenance Phase to Month 36
| Intervention | Percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Start of Maintenance Phase to Month 3 | Month 3 to Month 6 | Month 6 to Month 9 | Month 9 to Month 12 | Month 12 to Month 15 | Month 15 to Month 18 | Month 18 to Month 21 | Month 21 to Month 24 | Month 24 to Month 27 | Month 27 to Month 30 | Month 30 to Month 33 | Month 33 to Month 36 | |
| Azathioprine | 97.2 | 89.3 | 86.2 | 83.0 | 77.5 | 74.1 | 70.7 | 68.3 | 67.1 | 65.9 | 63.4 | 58.6 |
| Mycophenolate Mofetil | 98.2 | 93.7 | 89.9 | 86.0 | 86.0 | 84.9 | 84.9 | 83.9 | 82.8 | 82.8 | 81.7 | 81.7 |
16 reviews available for prednisone and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Recent Advances in Treatment Strategies for Lupus Nephritis.
Topics: Antihypertensive Agents; Antirheumatic Agents; Cyclophosphamide; Drug Therapy, Combination; Glucocor | 2018 |
2013 update: Hopkins lupus cohort.
Topics: Antirheumatic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Creatinine; Gluc | 2013 |
[Three cases of bullous lupus erythematosus].
Topics: Adult; Arthralgia; Autoantibodies; Blister; Collagen; Diagnosis, Differential; Disease Progression; | 2013 |
Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid | 2014 |
Pregnancies in women receiving renal transplant for lupus nephritis: description of nine pregnancies and review of the literature.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Antihypertensive Ag | 2015 |
Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid | 2015 |
[Lupus nephritis].
Topics: Antibodies, Antinuclear; Biopsy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administra | 1995 |
The course and treatment of lupus nephritis.
Topics: Azathioprine; Cyclophosphamide; Drug Combinations; Humans; Lupus Nephritis; Prednisone; Prognosis; W | 1994 |
Predominant tubulointerstitial lupus nephritis.
Topics: Acute Kidney Injury; Glucocorticoids; Humans; Kidney Glomerulus; Kidney Tubules; Lupus Nephritis; Ma | 1996 |
Treatment of lupus nephritis: a meta-analysis of clinical trials.
Topics: Adult; Azathioprine; Child; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunosuppr | 1997 |
[Lupus nephropathy--therapeutic options 1996].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Cyclophosphamide; Female; Humans; Immunosuppressi | 1997 |
Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Clinical Trials as Topic; Cyclophospha | 1999 |
Renal transplantation for systemic lupus erythematosus and recurrent lupus nephritis. A single-center experience and a review of the literature.
Topics: Adult; Animals; Antibodies, Antinuclear; Antilymphocyte Serum; Azathioprine; Complement System Prote | 1991 |
[Systemic lupus erythematosus and pregnancy].
Topics: Adult; Breast Feeding; Female; Glomerulonephritis; Humans; Infant, Newborn; Lupus Erythematosus, Sys | 1989 |
[Lupus nephropathy. II. Treatment].
Topics: Azathioprine; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Humans; Immunotherapy; L | 1989 |
Long-term prognosis of diffuse lupus nephritis.
Topics: Administration, Oral; Adolescent; Adult; Creatinine; Female; Follow-Up Studies; Humans; Infusions, I | 1987 |
48 trials available for prednisone and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.
Topics: Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Hum | 2022 |
Effectiveness of renoprotective approaches for persistent proteinuria in lupus nephritis: more than just immunosuppression.
Topics: Adult; Azathioprine; Blood Pressure; Brazil; Drug Therapy, Combination; Female; Humans; Immunosuppre | 2018 |
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Topics: Adult; Antibodies, Antinuclear; China; Complement C3; Cyclophosphamide; DNA; Drug Therapy, Combinati | 2019 |
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
Topics: Adolescent; Adult; Aged; Biopsy; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoid | 2015 |
Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephr | 2016 |
Successful treatment of class V+IV lupus nephritis with multitarget therapy.
Topics: Adult; Drug Therapy, Combination; Enzyme Inhibitors; Female; Glucocorticoids; Humans; Immunosuppress | 2008 |
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.
Topics: Adolescent; Adult; Age of Onset; Cyclophosphamide; Cyclosporine; Female; Hematocrit; Humans; Immunos | 2009 |
Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
Topics: Adolescent; Adult; Creatinine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosuppressive | 2010 |
Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combin | 2010 |
Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Complement System Proteins; | 2010 |
The prognosis of severe lupus nephritis based on the Modification of Diet in Renal Disease (MDRD) study estimated glomerular filtration rate.
Topics: Adult; Anti-Inflammatory Agents; Creatinine; Cyclophosphamide; Diet; Female; Glomerular Filtration R | 2011 |
Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial.
Topics: Adult; Anti-Inflammatory Agents; China; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Fem | 2011 |
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Dose-Response Relationship, Drug; Double-Blind Method; D | 2012 |
Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.
Topics: Administration, Oral; Adolescent; Age Factors; Asia; Azathioprine; Biomarkers; Creatinine; Cyclophos | 2012 |
Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
Topics: Administration, Intravenous; Adrenal Cortex Hormones; Adult; Creatinine; Cyclophosphamide; Dose-Resp | 2012 |
Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial.
Topics: Adult; Anti-Inflammatory Agents; Asian People; Azathioprine; Female; Humans; Immunosuppressive Agent | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cell Proliferation; Cyclophosphamide; Disease-Free Su | 2005 |
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Topics: Administration, Oral; Adult; Cross-Over Studies; Cyclophosphamide; Drug Therapy, Combination; Female | 2005 |
[Intervention of liuwei dihuang pill on lupus nephropathy treated with cylophosphamide and glucocorticoids].
Topics: Adolescent; Adult; Cyclophosphamide; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Human | 2005 |
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Topics: Administration, Oral; Adult; Azathioprine; Complement C3; Complement C4; Creatinine; Cyclophosphamid | 2006 |
The prognosis and pathogenesis of severe lupus glomerulonephritis.
Topics: Administration, Oral; Adult; Biopsy; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 2008 |
Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
Topics: Adult; Biopsy; Cyclophosphamide; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki | 1994 |
Therapy of lupus nephritis. A two-year prospective study.
Topics: Adolescent; Adult; Aged; Azathioprine; Combined Modality Therapy; Drug Therapy, Combination; Humans; | 1994 |
[Therapy of integrated traditional Chinese medicine and Western medicine on 74 lupus nephritis].
Topics: Adolescent; Adult; Child; Cyclophosphamide; Drug Therapy, Combination; Drugs, Chinese Herbal; Female | 1994 |
Early and intensive treatment of lupus nephritis with pulse cyclophosphamide.
Topics: Cyclophosphamide; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lupus Nephri | 1993 |
Gallium-67 scintigraphy to predict response to therapy in active lupus nephritis.
Topics: Adult; Aged; Creatinine; Cyclophosphamide; Female; Follow-Up Studies; Gallium Radioisotopes; Humans; | 1998 |
Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression.
Topics: Adult; Alopecia; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Ther | 1999 |
[Clinical observation on nephrotic syndrome of lupus nephritis treated with integrated traditional Chinese and Western Medicine].
Topics: Adolescent; Adult; Child; Cyclophosphamide; Drug Therapy, Combination; Drugs, Chinese Herbal; Female | 1998 |
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Creatinine; Cyclophosphamide; Drug Administration Schedule; Drug Th | 2001 |
Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therap | 2001 |
Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; Drug Therapy, Combination; Humans; Immu | 2001 |
Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group.
Topics: Adult; Cyclophosphamide; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Middl | 1992 |
Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study.
Topics: Combined Modality Therapy; Cyclophosphamide; Data Interpretation, Statistical; Follow-Up Studies; Hu | 1992 |
Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis.
Topics: Creatinine; Cyclosporine; Drug Therapy, Combination; Humans; Lupus Nephritis; Prednisone; Proteinuri | 1992 |
Treatment of diffuse proliferative lupus nephritis.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; | 1992 |
Approach to lupus nephritis based upon randomized trials.
Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lupus Nephritis; Male; Me | 1992 |
Plasmapheresis for lupus nephritis.
Topics: Combined Modality Therapy; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; | 1992 |
Plasmapheresis for lupus nephritis. Lupus Plasmapheresis Study Group.
Topics: Combined Modality Therapy; Cyclophosphamide; Humans; Lupus Nephritis; Plasmapheresis; Prednisone | 1992 |
Plasmapheresis for lupus nephritis.
Topics: Combined Modality Therapy; Cyclophosphamide; Humans; Lupus Nephritis; Plasmapheresis; Prednisone; Re | 1992 |
Plasmapheresis for lupus nephritis.
Topics: Combined Modality Therapy; Cyclophosphamide; Humans; Lupus Nephritis; Plasmapheresis; Prednisone | 1992 |
A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
Topics: Adult; Autoantibodies; Combined Modality Therapy; Creatinine; Cryoglobulins; Cyclophosphamide; DNA; | 1992 |
Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Combined Modality Therapy; Creatinine | 1992 |
[The efficacy of cyclophosphamide bolus therapy in a girl with SLE with a nephritic onset].
Topics: Biopsy; Child; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Kidney; | 1991 |
Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Cyclophosphamide; Dose-Response Relationship, | 1991 |
Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
Topics: Adult; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Disease Susceptibility; Female; | 1991 |
Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group.
Topics: Adult; Biopsy; Cyclophosphamide; Female; Humans; Kidney; Kidney Failure, Chronic; Lupus Nephritis; M | 1989 |
Intermittent intravenous cyclophosphamide therapy for lupus nephritis.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Lupus | 1989 |
148 other studies available for prednisone and Glomerulonephritis, Lupus
| Article | Year |
|---|---|
Good pregnancy outcomes in lupus nephritis patients with complete renal remission.
Topics: Adult; Female; Humans; Lupus Nephritis; Prednisone; Pregnancy; Pregnancy Complications; Pregnancy Ou | 2022 |
Lupus podocytopathy superimposed on diabetic glomerulosclerosis: A case report.
Topics: Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Glucocorticoids; Humans; Insulin Infusion | 2021 |
Novel Effects of Combination Therapy Through Inhibition of Caspase-1/Gasdermin D Induced-Pyroptosis in Lupus Nephritis.
Topics: Adolescent; Adult; Aged; Animals; Calcineurin Inhibitors; Caspase 1; Caspase Inhibitors; Cells, Cult | 2021 |
Jieduquyuziyin prescription promotes the efficacy of prednisone via upregulating Nrf2 in MRL/lpr kidneys.
Topics: Animals; Drugs, Chinese Herbal; Female; Kidney; Lupus Nephritis; Mice; Mice, Inbred MRL lpr; Prednis | 2022 |
Estimating glucocorticoid-related morbidity in lupus nephritis using the glucocorticoid toxicity index.
Topics: Adult; Cohort Studies; Glucocorticoids; Humans; Kidney; Lupus Erythematosus, Systemic; Lupus Nephrit | 2023 |
Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy.
Topics: Animals; Autophagy; Bronchiolitis Obliterans Syndrome; Kidney; Lupus Erythematosus, Systemic; Lupus | 2023 |
Improving Outcomes of Pediatric Lupus Care Delivery With Provider Goal-Setting Activities and Multidisciplinary Care Models.
Topics: Adolescent; Child; Delivery of Health Care; Goals; Humans; Lupus Erythematosus, Systemic; Lupus Neph | 2023 |
The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
Topics: Animals; Blood Urea Nitrogen; Complement Activation; Complement Inactivating Agents; Creatinine; Fem | 2019 |
Cryptococcal meningitis in patients with lupus nephritis.
Topics: Adult; Case-Control Studies; CD4 Lymphocyte Count; Female; Fever; Glucocorticoids; Headache; Humans; | 2020 |
Case report: A kidney transplant patient with mild COVID-19.
Topics: Adult; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Tre | 2020 |
Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Topics: Adult; Azathioprine; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Drug The | 2020 |
Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Linear Model | 2020 |
Anti-nucleosome antibodies increase the risk of renal relapse in a prospective cohort of patients with clinically inactive systemic lupus erythematosus.
Topics: Administration, Oral; Adult; Antibodies, Antinuclear; Asymptomatic Diseases; DNA; Female; Humans; Im | 2020 |
Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biomarkers; Case-Control Studies; Complement | 2020 |
Predictors of renal damage in systemic lupus erythematous patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL).
Topics: Cohort Studies; Humans; Latin America; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Prednis | 2020 |
Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score-Matched Analysis.
Topics: Cyclophosphamide; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Nephritis; Prednisone; Pr | 2022 |
Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
Topics: Adult; Biopsy; Creatinine; Female; Humans; Immunosuppressive Agents; Kidney; Logistic Models; Lupus | 2022 |
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Aspirin; Drug Tapering; Europe; Fema | 2021 |
A Pregnant Woman with Lupus and Nephrotic-Range Proteinuria.
Topics: Biopsy; Drug Administration Schedule; Female; Glucocorticoids; Humans; Lupus Nephritis; Prednisone; | 2017 |
Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
Topics: Adult; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoid | 2017 |
Cognitive Function in Children with Lupus Nephritis: A Cross-Sectional Comparison with Children with Other Glomerular Chronic Kidney Diseases.
Topics: Adolescent; Child; Child, Preschool; Cognition; Cohort Studies; Cross-Sectional Studies; Female; Glo | 2017 |
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
Topics: Adolescent; Adult; Aged; Azathioprine; China; Cyclophosphamide; Drug Therapy, Combination; Female; H | 2017 |
Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis.
Topics: Animals; Cytoskeleton; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Ge | 2018 |
[Pregnancy outcome in a woman with premature ovarian insufficiency complicated by systemic lupus erythematosus during pregnancy: a case report].
Topics: Aspirin; Cesarean Section; Embryo Transfer; Female; Fertilization in Vitro; Humans; Lupus Erythemato | 2017 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Prednisone in lupus nephritis: how much is enough?
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Hydroxychloroqu | 2014 |
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort.
Topics: Adult; Anemia; Black or African American; Cohort Studies; Cost-Benefit Analysis; Female; Health Care | 2015 |
Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Drug T | 2014 |
Lupus nephritis in Croatian children: clinicopathologic findings and outcome.
Topics: Adolescent; Child; Child, Preschool; Croatia; Female; Humans; Kidney; Lupus Nephritis; Male; Prednis | 2015 |
Celebrating the ACP centennial: from the Annals archive.
Topics: Azathioprine; Cyclophosphamide; Female; Glomerulonephritis; Glucocorticoids; Humans; Immunosuppressi | 2015 |
Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre.
Topics: Adolescent; Adult; Egypt; Female; Humans; Immunosuppressive Agents; Lupus Nephritis; Male; Prednison | 2015 |
Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study.
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Unilateral Perivascular Infiltrates in Lupus Retinopathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antinuclear; Autoantigens; Drug Therapy, Combin | 2015 |
New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Disease Progression; Drug Therapy, Combinati | 2017 |
Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Topics: Adult; Arthritis; Cataract; Cohort Studies; Diabetes Mellitus; Disease Progression; Female; Glucocor | 2017 |
[Analysis of pregnancy outcomes in 66 patients with systemic lupus erythematosus].
Topics: Birth Weight; Female; Humans; Infant, Newborn; Lupus Erythematosus, Systemic; Lupus Nephritis; Predn | 2016 |
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Autoantibodies; Bortezomib; Drug Therapy, | 2017 |
Primary Tuberculous Pyomyositis of the Calf Muscles.
Topics: Adult; Female; Fever; Humans; Immunocompromised Host; Lupus Erythematosus, Systemic; Lupus Nephritis | 2017 |
Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
Topics: Child; Child, Preschool; Clinical Protocols; Cyclophosphamide; Disease-Free Survival; Female; Follow | 2017 |
[Vasculitis as a reason of chronic headache].
Topics: Adolescent; Anemia, Hemolytic, Autoimmune; Chorea; Cyclophosphamide; Diagnosis, Differential; Drug T | 2008 |
T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis.
Topics: Anti-Inflammatory Agents; Complement C4; Cryoglobulins; Female; Fluorescent Antibody Technique; Huma | 2008 |
A clinicopathological study of lupus nephritis in children.
Topics: Adolescent; Biopsy; Child; Cyclophosphamide; Disease Progression; Female; Humans; Iran; Kidney; Kidn | 2008 |
The effectiveness and safety of mycophenolate mofetil in lupus nephritis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Drug Therapy, Combination; F | 2009 |
Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis.
Topics: Adolescent; Adult; Antibodies, Antineutrophil Cytoplasmic; Asian People; China; Female; Glucocortico | 2009 |
Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Topics: Adolescent; Azathioprine; Child; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy | 2009 |
Treatment of systemic lupus erythematosus in two patients with extreme B-cell lymphopenia: importance of immunomonitoring and avoidance of B-cell targeted therapy.
Topics: Adult; B-Lymphocytes; Blood Pressure; Creatinine; Cyclophosphamide; Fatal Outcome; Female; Humans; I | 2010 |
Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice.
Topics: Adult; Atherosclerosis; Biomedical Research; Female; Humans; Lupus Erythematosus, Systemic; Lupus Ne | 2011 |
[Intestinal halo sign in systemic lupus erythematosus].
Topics: Adult; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Humans; Hydronephrosis; Intestinal | 2011 |
[Cyclophosphamide-induced lupus flare in diffuse proliferative lupus nephropathy].
Topics: Acute Disease; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; | 2011 |
Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor α mRNA, glucocorticoid receptor β mRNA and P300/CBP protein in lupus nephritis mice.
Topics: Animals; Artemisinins; Base Sequence; Disease Models, Animal; DNA Primers; Electrophoresis, Agar Gel | 2011 |
The dynamics of urinary N-acetyl-β-D-glucosaminidase (NAG), a marker of renal tubular dysfunction, in patients with lupus nephritis undergoing oral prednisone therapy.
Topics: Acetylglucosaminidase; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents; Biomarkers | 2012 |
Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis.
Topics: Adult; Azathioprine; Creatinine; Cyclophosphamide; Drug Therapy, Combination; Female; Glomerulonephr | 2011 |
Protein-losing enteropathy as initial manifestation of systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Azathioprine; Biomarkers; Complement C3; Diarrhea; Drug Therapy | 2012 |
Trilineage myelodysplasia and hemophagocytosis associated with systemic lupus erythematosus.
Topics: Acute Kidney Injury; Adult; Blood Component Transfusion; Bone Marrow; Cell Lineage; Combined Modalit | 2012 |
[Lupus, Graves' disease, and vasculitis: a case report].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoantibodies; Cushing Syndrome; Dipyro | 2012 |
Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange.
Topics: Acute Kidney Injury; Adult; Biopsy; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combi | 2012 |
Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy.
Topics: Adult; Antimalarials; Azathioprine; Comorbidity; Drug Therapy, Combination; Female; Fetal Diseases; | 2012 |
[Proliferative mesangial lupus nephritis: description of a cohort of 27 patients].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Disease Progression; Drug Administration Schedule; Drug | 2012 |
Mycophenolate as induction therapy in lupus nephritis with renal function impairment.
Topics: Adult; Antibiotics, Antineoplastic; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Ag | 2012 |
Minimal-change nephropathy in systemic lupus erythematosus.
Topics: Anti-Inflammatory Agents; Diagnosis, Differential; Edema; Female; Humans; Hypertension, Renal; Immun | 2012 |
[Effect of artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice].
Topics: Animals; Artemisia annua; Artemisinins; Disease Models, Animal; Female; Leukocytes, Mononuclear; Lup | 2012 |
APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis.
Topics: Adult; B-Cell Activating Factor; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Enzyme-Lin | 2012 |
Long-term renal outcome and complications in South Africans with proliferative lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Blood Pressure; Creatinine; Cyclophosphamide; Disease | 2013 |
Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China.
Topics: Cyclophosphamide; Humans; Immunosuppressive Agents; Kidney; Lupus Nephritis; Prednisone | 2002 |
Lupus choroidopathy and choroidal effusions.
Topics: Adult; Antirheumatic Agents; Azathioprine; Choroid Diseases; Ciliary Body; Drug Therapy, Combination | 2002 |
Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil.
Topics: Adolescent; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Hemorrhage; H | 2003 |
Corticosteroid therapy in lupus nephritis. Importance of adequate dosage.
Topics: Adrenal Cortex Hormones; Glomerulonephritis; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; | 1961 |
Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis.
Topics: Glomerulonephritis; Humans; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Prednisone | 1961 |
Lupus nephritis. Clinical and histologic survey.
Topics: Adrenocorticotropic Hormone; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Mechlorethamine | 1963 |
LUPUS GLOMERULONEPHRITIS. THE EFFECT OF LARGE DOSES OF CORTICOSTEROIDS ON RENAL FUNCTION AND RENAL LESIONS IN TWO CHILDREN.
Topics: Adolescent; Adrenal Cortex Hormones; Cortisone; Drug Therapy; Glomerulonephritis; Guanethidine; Hydr | 1965 |
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Arteriosclerosis; Carotid Arteries; Cross-Sectional St | 2003 |
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Arteriosclerosis; Carotid Arteries; Cross-Sectional St | 2003 |
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Arteriosclerosis; Carotid Arteries; Cross-Sectional St | 2003 |
Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Arteriosclerosis; Carotid Arteries; Cross-Sectional St | 2003 |
Remission of refractory lupus nephritis with a protocol including rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclop | 2003 |
Questions & answers. My doctor told me I might develop Cushing's syndrome because of the prednisone I take for kidney disease caused by lupus. What symptoms should I expect?
Topics: Cushing Syndrome; Glucocorticoids; Humans; Lupus Nephritis; Prednisone | 2003 |
Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclophosphamide; Dose-Response Relationship, | 2003 |
Cyclosporine A in treatment of membranous lupus nephropathy.
Topics: Adolescent; Adult; Cyclosporine; Female; Glomerulonephritis, Membranous; Humans; Lupus Nephritis; Ma | 2003 |
Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis.
Topics: Blood Proteins; Chronic Disease; Complement C3; Creatinine; Cyclophosphamide; Drug Therapy, Combinat | 2004 |
Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study.
Topics: Actins; Adolescent; Adult; Chronic Disease; Collagen; Drug Therapy, Combination; Female; Fibronectin | 2004 |
Clinicopathological study of the WHO classification in childhood lupus nephritis.
Topics: Adolescent; Alkylating Agents; Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Biopsy; Bloo | 2004 |
Clinical predictors of recovery and complications in the management of recent-onset renal failure in lupus nephritis: a Chinese experience.
Topics: Adult; China; Cohort Studies; Cyclophosphamide; Female; Forecasting; Glucocorticoids; Humans; Immuno | 2004 |
Acquired ichthyosis associated with systemic lupus erythematosus.
Topics: Administration, Oral; Adult; Cyclophosphamide; Female; Humans; Ichthyosis; Immunosuppressive Agents; | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid | 2004 |
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Topics: Adult; Azathioprine; Biopsy; Complement C3; Creatinine; Cyclophosphamide; Female; Humans; Kidney; Ki | 2004 |
Isaacs' syndrome (autoimmune neuromyotonia) in a patient with systemic lupus erythematosus.
Topics: Amines; Anticonvulsants; Autoantibodies; Azathioprine; Clonazepam; Cyclohexanecarboxylic Acids; Drug | 2005 |
The course of anticardiolipin antibody levels under immunoadsorption therapy.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Antibodies, Anticardiolipin; Antibodies, Antinucle | 2005 |
Propylthiouracil-induced lupus-like syndrome: successful management with oral corticosteroids.
Topics: Female; Goiter, Nodular; Humans; Lupus Nephritis; Middle Aged; Prednisone; Propylthiouracil | 2005 |
[Lupus nephritis, mycophenolate, and cytomegalovirus infection].
Topics: Adult; Antibodies, Viral; Cyclophosphamide; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infection | 2006 |
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Hematuria in a patient with class IV lupus nephritis.
Topics: Antihypertensive Agents; Biopsy; Cyclophosphamide; El Salvador; Female; Follow-Up Studies; Glomerula | 2006 |
Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide.
Topics: Administration, Oral; Adult; Cross-Over Studies; Cyclophosphamide; Drug Therapy, Combination; Female | 2006 |
[Influential factors of systemic lupus erythematosus activity during pregnancy and its relationship with pregnancy outcome].
Topics: Abortion, Spontaneous; Adult; Female; Fetal Death; Fetal Growth Retardation; Gestational Age; Humans | 2006 |
Histologic deterioration and more flares: the case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis.
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Creatinine; Cyclophosphamide; Dose-Response Relation | 2007 |
Maternal and fetal outcomes of 72 pregnancies in Argentine patients with systemic lupus erythematosus (SLE).
Topics: Adult; Antiphospholipid Syndrome; Argentina; Comorbidity; Female; Humans; Infant, Low Birth Weight; | 2008 |
Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with systemic lupus erythematosus (SLE) and lupus nephritis.
Topics: Adult; Brain; Cerebrovascular Disorders; Comorbidity; Female; Humans; Hydrocortisone; Kidney Disease | 2007 |
[Interdisciplinary consensus to management of lupus nephritis in Germany].
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunos | 2007 |
Evaluation of lupus nephritis during pregnancy by renal biopsy.
Topics: Adult; Biopsy; Cyclophosphamide; Female; Follow-Up Studies; Humans; Kidney; Kidney Failure, Chronic; | 1995 |
Clinical problem solving. The girl with the curl.
Topics: Acyclovir; Antitubercular Agents; Cyclosporine; Female; Fever; Herpesvirus 4, Human; Humans; Immunos | 1995 |
[Monthly intravenous cyclophosphamide in the treatment of lupus nephritis].
Topics: Adolescent; Adult; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Infusions, Intrav | 1994 |
Renal transplantation in systemic lupus erythematosus: a single-center experience with sixty-four cases.
Topics: Adult; Azathioprine; Cadaver; Cyclosporine; Female; Graft Survival; Humans; Immunosuppression Therap | 1995 |
Therapy of proliferative lupus glomerulonephritis: a prospective trial in The Netherlands.
Topics: Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; Lupus N | 1994 |
The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide.
Topics: Adult; Costs and Cost Analysis; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Injecti | 1994 |
[Lupus erythematosus disseminatus and Pneumocystis carinii pneumonia].
Topics: Bronchoalveolar Lavage Fluid; Cyclophosphamide; Female; Humans; Lung; Lupus Erythematosus, Systemic; | 1993 |
Treatment of end-stage renal disease due to lupus nephritis: comparison of six patients treated with both peritoneal and hemodialysis.
Topics: Adolescent; Adult; Age of Onset; Female; Humans; Kidney Failure, Chronic; Lupus Erythematosus, Syste | 1993 |
Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Complement C3; Complement C4; Creatinine; Dose-Respon | 1994 |
Lipoprotein(a) levels in systemic lupus erythematosus.
Topics: Adult; Antibodies, Anticardiolipin; Female; Humans; Lipoprotein(a); Lupus Erythematosus, Systemic; L | 1994 |
Lupus and its management.
Topics: Adolescent; Antibiotics, Antineoplastic; Autoantibodies; Azathioprine; Cyclophosphamide; Dose-Respon | 1993 |
Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy.
Topics: Adolescent; Adult; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lupus | 1993 |
[Lupus nephritis in male adults, an analysis of the clinical and pathological features].
Topics: Adolescent; Adult; Age Factors; Aged; Female; Glucocorticoids; Humans; Kidney; Lupus Nephritis; Male | 1995 |
Lupus nephritis in children: a longitudinal study of prognostic factors and therapy.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio | 1996 |
Systemic lupus erythematosus [clinical inference].
Topics: Adult; Antiphospholipid Syndrome; Azathioprine; Cyclophosphamide; Female; Humans; Lupus Erythematosu | 1997 |
Methotrexate in systemic lupus erythematosus.
Topics: Adult; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Methotrexate; Prednisone | 1997 |
Lupus and cerebrovascular accidents.
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Autoimmune Diseases; | 1997 |
The prognosis of biopsy-proven lupus nephritis in chinese patients: long term follow-up of 86 cases.
Topics: Adult; Biopsy, Needle; Cyclophosphamide; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; I | 1997 |
[Attention should be paid to the research on lupus glomerulonephritis].
Topics: Anti-Inflammatory Agents; Antibodies, Antinuclear; Cyclophosphamide; Humans; Immunosuppressive Agent | 1997 |
[Management of lupus nephritis in Senegal].
Topics: Amenorrhea; Anti-Inflammatory Agents; Autoimmune Diseases; Cyclophosphamide; Female; Femur Head Necr | 1997 |
[Factors analysis of pregnancy success in chronic glomerulus diseases].
Topics: Adult; Anti-Inflammatory Agents; Female; Glomerulonephritis; Humans; Lupus Nephritis; Nephrotic Synd | 1997 |
Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Anti-Inflammatory Agents; Biopsy; Cause of Death; Chil | 1999 |
A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.
Topics: Adult; Alkylating Agents; Anti-Inflammatory Agents; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-P | 1999 |
Intravenous immunoglobulin treatment of lupus nephritis.
Topics: Adolescent; Adult; Biomarkers; Cyclophosphamide; Drug Resistance; Female; Humans; Immunoglobulins, I | 2000 |
"Pauci-Immune" proliferative and necrotizing glomerulonephritis with thrombotic microangiopathy in patients with systemic lupus erythematosus and lupus-like syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Anticardiolipin; Antibodies, Antineutrophil Cytop | 2000 |
Lupus nephritis and the anti-phospholipid antibody syndrome in pregnancy.
Topics: Abortion, Induced; Adult; Antiphospholipid Syndrome; Cyclophosphamide; Female; Glucocorticoids; Huma | 2000 |
Lupus nephritis in children: prognostic significance of clinicopathological findings.
Topics: Adolescent; Anemia; Blood Pressure; Child; Child, Preschool; Creatinine; Cyclophosphamide; Female; H | 2001 |
[Appraisal of renal failure reversing therapies in lupus nephritis].
Topics: Administration, Oral; Cohort Studies; Cyclophosphamide; Cyclosporine; Dexamethasone; Female; Follow- | 2001 |
Flaccid paresis due to distal renal tubular acidosis preceding systemic lupus erythematosus.
Topics: Acidosis, Renal Tubular; Adult; Female; Follow-Up Studies; Humans; Kidney Function Tests; Lupus Eryt | 2002 |
[Treatment of lupus erythematosus with integrated traditional Chinese medicine and Western medicine].
Topics: Drugs, Chinese Herbal; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Prednisone; Tripteryg | 1992 |
Recurrence of membranous lupus glomerulonephritis two months after a renal cadaver transplant.
Topics: Adult; Azathioprine; Cyclosporine; Humans; Immunosuppression Therapy; Kidney Transplantation; Lupus | 1992 |
A critique of the NIH lupus nephritis survey.
Topics: Cyclophosphamide; Health Surveys; Humans; Injections, Intravenous; Kidney; Lupus Nephritis; National | 1992 |
Can ciclosporin A be used without steroids in systemic lupus erythematosus?
Topics: Adult; Cyclosporins; Drug Therapy, Combination; Female; Humans; Lupus Erythematosus, Systemic; Lupus | 1991 |
Lupus nephritis: therapeutic decisions.
Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Kidney Glomerulus; | 1990 |
Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.
Topics: Adult; Ancrod; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Follow-Up Studies; Hum | 1990 |
Multiple brain abscesses from isolated cerebral mucormycosis.
Topics: Adult; Brain Abscess; Cyclophosphamide; Female; Frontal Lobe; Humans; Lupus Erythematosus, Systemic; | 1990 |
Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.
Topics: Clinical Protocols; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1990 |
[Systemic lupus erythematosus and pregnancy. Clinical aspects, serology and management].
Topics: Antibodies, Antinuclear; Azathioprine; Female; Fetal Death; Humans; Infant, Newborn; Lupus Erythemat | 1990 |
[Evaluation of long-term immunotherapy in patients with lupus nephritis].
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Immunotherapy; Levamisole; Lupus Nephritis; Pre | 1989 |
Effect of long-term normalization of serum complement levels on the course of lupus nephritis.
Topics: Azathioprine; Complement System Proteins; Drug Administration Schedule; Female; Follow-Up Studies; H | 1989 |
Hypertension in children with systemic lupus erythematosus.
Topics: Adolescent; Antihypertensive Agents; Child; Female; Glomerulonephritis, Membranoproliferative; Human | 1989 |
Poor prognosis in end-stage lupus nephritis due to nonautologous vascular access site associated septicemia and lupus flares.
Topics: Adult; Bacterial Infections; Cyclophosphamide; Female; Humans; Kidney Failure, Chronic; Lupus Erythe | 1989 |
Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Nephritis; Mal | 1989 |
Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis.
Topics: Aged; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Inj | 1988 |
The wolf inside.
Topics: Adult; Female; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Pericarditis; Prednisone | 1988 |
[Corticosteroids administered in bolus in lupus nephropathy].
Topics: Adrenal Cortex Hormones; Adult; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Infusion | 1986 |
Discontinuation of therapy in diffuse proliferative lupus nephritis.
Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Humans; Lupus Nephriti | 1988 |
Lupus nephritis: a 13-year experience.
Topics: Adolescent; Adult; Azathioprine; Biopsy; Child; Female; Follow-Up Studies; Humans; Kidney; Lupus Nep | 1986 |
Persistence of clinical and serologic activity in patients with systemic lupus erythematosus undergoing peritoneal dialysis.
Topics: Adult; Antibodies, Antinuclear; Complement C3; Complement C4; Female; Humans; Kidney Failure, Chroni | 1987 |
Systemic lupus erythematosus--the nephrologist's viewpoint.
Topics: Azathioprine; Cyclophosphamide; Female; Humans; Lupus Nephritis; Male; Mechlorethamine; Prednisone; | 1987 |
Histologic features that correlate with the prognosis of patients with lupus nephritis.
Topics: Biopsy; Humans; Kidney Glomerulus; Lupus Nephritis; Prednisone; Prognosis | 1987 |
Lupus nephritis after total lymphoid irradiation: persistent improvement and reduction of steroid therapy.
Topics: Complement C3; Follow-Up Studies; Humans; Lupus Nephritis; Lymphoid Tissue; Prednisone; Proteinuria; | 1987 |
The diagnosis and management of systemic lupus erythematosus in childhood.
Topics: Child; Cyclophosphamide; Humans; Lupus Erythematosus, Systemic; Lupus Nephritis; Prednisone; Salicyl | 1986 |
Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis.
Topics: Adolescent; Adult; Blood Pressure; Child; Complement C3; Complement C4; Creatinine; Drug Administrat | 1986 |